



Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits

Shreyasi Chatterjee* and Amritpal Mudher

Centre of Biological Sciences, University of Southampton, Southampton, United Kingdom

OPEN ACCESS

Edited by:

Athanasios Alexiou,
Novel Global Community Educational
Foundation (NGCEF), Hebersham,
Australia

Reviewed by:

Roland Brandt,
University of Osnabrück, Germany
Subashchandra Chinnathambi,
National Chemical Laboratory (CSIR),
India

*Correspondence:

Shreyasi Chatterjee
s.chatterjee@soton.ac.uk

Specialty section:

This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neuroscience

Received: 31 January 2018

Accepted: 22 May 2018

Published: 08 June 2018

Citation:

Chatterjee S and Mudher A (2018)
Alzheimer's Disease and Type 2
Diabetes: A Critical Assessment of the
Shared Pathological Traits.
Front. Neurosci. 12:383.
doi: 10.3389/fnins.2018.00383

Alzheimer's disease (AD) and Type 2 Diabetes Mellitus (T2DM) are two of the most prevalent diseases in the elderly population worldwide. A growing body of epidemiological studies suggest that people with T2DM are at a higher risk of developing AD. Likewise, AD brains are less capable of glucose uptake from the surroundings resembling a condition of brain insulin resistance. Pathologically AD is characterized by extracellular plaques of A β and intracellular neurofibrillary tangles of hyperphosphorylated tau. T2DM, on the other hand is a metabolic disorder characterized by hyperglycemia and insulin resistance. In this review we have discussed how Insulin resistance in T2DM directly exacerbates A β and tau pathologies and elucidated the pathophysiological traits of synaptic dysfunction, inflammation, and autophagic impairments that are common to both diseases and indirectly impact A β and tau functions in the neurons. Elucidation of the underlying pathways that connect these two diseases will be immensely valuable for designing novel drug targets for Alzheimer's disease.

Keywords: insulin resistance, tau proteins, abeta oligomers, synaptic dysfunction, autophagy, inflammation

INTRODUCTION

Alzheimer's Disease: Neuropathological Alterations and Metabolic Risk Factors

Diagnosed by the German psychiatrist and neuropathologist, Prof. Alois Alzheimer in 1906, Alzheimer's disease is the most prevalent form of dementia in the aging population (van der Flier and Scheltens, 2005). Recently declared as the sixth major cause of death in the world, patients affected with AD suffer a gradual decline of cognitive abilities and memory functions till the disease renders them incapable of performing daily functions (James et al., 2014). Statistical data reveals that over 30 million people are suffering from AD worldwide and this number is estimated to double every 20 years to reach 66 million in 2030 and about 115 million by 2050¹.

Clinically AD can be classified into two subtypes. About 95% of AD patients are aged 65 years or older and are diagnosed with "late-onset" or "sporadic AD" (sAD) while 5% of AD patients carry rare genetic mutations associated with "early-onset" or "familial AD" (fAD) that causes the onset of disease symptoms in a person's thirties, forties, or fifties (De Strooper, 2007). In early onset fAD, the disease pathology is caused by mutation in three known genes namely: amyloid precursor protein (APP), presenilin-1 (PS-1), and presenilin-2 (PS-2). Although PS-1 mutations account for most of the fAD, there are mutations outside these three genes that are yet unknown. Unlike the fAD, the genetics of sAD is more complex (Dorszewska et al., 2016).

¹ Available online at: <https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf>.

Other than aging, which is the strongest risk factor for sAD, GWAS studies reveal that the epsilon four allele of the apolipoprotein E (ApoE4) gene is a significant risk factor for the development of this disease. Two copies of ApoE4 gene increases risk of AD by 12-fold, while one copy of this allele enhances the risk by 4-fold (Bertram and Tanzi, 2009). However, only 50–60% individuals are carriers of this gene suggesting that other factors also confer risk. Studies suggest that these include factors such as cerebrovascular infarction, family history of diabetes, hypertension, and obesity (Li et al., 2015a).

At a cellular level, AD is characterized by a progressive loss of pyramidal cells in the entorhinal cortex and CA1 region of the hippocampus that are responsible for maintenance of higher cognitive functions (Serrano-Pozo et al., 2011). Early symptoms of AD are also marked by synaptic dysfunction that disrupts connectivity between neural circuits, thereby initiating the gradual loss of memory.

Neuropathologically, AD is characterized by extracellular plaques of insoluble amyloid- β protein, and intracellular neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein (Iqbal et al., 2010; Serrano-Pozo et al., 2011). In AD, abnormal cleavage of APP results in the formation of insoluble amyloid- β protein, densely packed with beta sheets, which form the core of the senile plaques (Serpell et al., 2000). Tau protein, in a physiological state serves as a microtubule binding protein and plays an important role in axonal and vesicular transport (Mandelkow and Mandelkow, 1995). Conversely, in the disease state tau protein is hyperphosphorylated and detached from the microtubules. In animal models this phospho-tau-mediated disruption of cytoskeletal integrity manifests in synaptic and behavioral impairments (Mudher et al., 2004; Quraishe et al., 2013; Gilley et al., 2016; Lathuilière et al., 2017). Although a large body of *in vitro* studies have investigated tau-microtubule binding interactions, most of these studies have been conducted *in silico* or in non-neural cellular models (Kadavath et al., 2015; Huda et al., 2017). In a series of elegant experiments involving single-molecule tracking of tau in axonal processes, Niewidok et al. and Janning et al. have shown that the interaction of tau with the microtubules follows a “kiss-and-hop” mechanism. Their studies show that a single tau molecule resides only 40 ms on a particular microtubule and then hops longitudinally and transversely on adjacent microtubules. This novel mechanism has been particularly effective in resolving the paradoxical observation that despite regulating microtubule dynamics, alterations in tau levels may not interfere with axonal transport (Janning et al., 2014; Niewidok et al., 2016). Using pseudo-hyperphosphorylated tau constructs they observed a considerable weakening of the tau-microtubule interactions that corroborated with previous *in vitro* studies.

A large body of evidence supports the idea that the formation of A β plaques occurs 15–20 years earlier before the cognitive functions decline, whereas the spatial and temporal spread of tau pathology correlates more strongly with the severity with disease progression (Serrano-Pozo et al., 2011; Vlassenko et al., 2012). Although A β and tau are the pathological hallmarks that characterize sAD, it is not yet clear whether these two factors trigger AD or if they are manifested as the effect of the disease.

The drug therapy of AD is still at a nascent stage providing symptomatic relief but not slowing down disease progression. Such treatments include FDA-approved choline esterase inhibitors and NMDA (glutamate) receptor agonists. Thus, from a public health perspective AD exerts a significant healthcare burden that is expected to escalate 5-fold in the coming decades. Hence, the need for early detection and effective treatment is an urgent priority (Yiannopoulou and Papageorgiou, 2013).

In recent times, it has been hypothesized that various risk factors promote A β and tau-related pathological changes before the onset of clinical symptoms in AD. One of the formidable challenges of the twenty-first century is to identify these risk factors and enable early detection of pathophysiological alterations at the cellular and biochemical level so that effective treatments can be designed against this devastating disease. A significant risk factor associated with sAD that has received a considerable attention in recent times is Type 2 Diabetes (T2D) (Li et al., 2015a).

Type 2 Diabetes

Diabetes mellitus is a chronic metabolic disorder that is increasing worldwide at an alarming rate. It is estimated that 387 million people are affected by Type1 and T2DM and this number is expected to reach 552 million by 2030 (American Diabetes, 2009). The financial costs for the treatment of diabetes and support for the patients presents a significant healthcare challenge for any country across the world.

The most prevalent subtype of diabetes is the Type 2 diabetes mellitus (T2DM) that comprises 95% of this disease. The salient features of T2DM are high levels of blood glucose (hyperglycaemia), hyper-insulinemia, and insulin resistance (Taylor, 2012). Insulin resistance arises due to decreased insulin sensitivity of muscle, liver, and fat cells to insulin. Another prominent feature of T2DM is the formation of human islet amyloid polypeptide that causes pancreatic β -cell dysfunction (Marzban et al., 2003). Both these features ultimately result in a reduced uptake of circulating blood glucose for glycogenesis eventually leading to chronic hyperglycemia as one of the pathological hallmarks of T2DM.

What is the evidence that there is a patho-physiological link between Diabetes and AD?

Evidence From Epidemiological Studies

Epidemiological studies show that T2DM increases the risk of AD by at least 2-fold (Barbagallo and Dominguez, 2014). In a study cohort recruited from Manhattan in 1992–1994 and then in 1999–2001 Cheng et al. demonstrated that T2DM is associated strongly with late-onset AD (LOAD) after adjustment of sex and age. Their findings also suggested that the link between T2DM and LOAD is partly mediated by cerebrovascular pathology (Cheng et al., 2011). Recent studies from Li et al. report that T2DM in an elderly Chinese population with mild cognitive impairment (MCI) influences the progression to AD, while no change is observed in age-matched controls (Li et al., 2016). These data are supported by longitudinal studies conducted by Leibson et al. and Huang et al. in which patients with adult onset

diabetes exhibited a significantly higher risk of developing AD than age-matched subjects without T2DM (Leibson et al., 1997; Huang et al., 2014). Epidemiological studies have also examined the association between ApoE4 genotype and diabetes or insulin resistance, although the reports are controversial. For instance, a longitudinal study in Japanese-American men demonstrated that ApoE4 increases the risk of LOAD in individuals with T2DM (Peila et al., 2002). In contrast, population-based studies conducted by Marseglia et al. show an association between T2DM and risk of dementia only in ApoE4 non-carriers (Marseglia et al., 2016).

Evidence From Neuroimaging Studies

The evidence from epidemiological studies has recently been corroborated by findings from neuroimaging studies (PET and MRI) that monitor the structural alterations in brains of patients affected by AD and T2DM. The data from the neuroimaging studies reveals a considerable overlap between the vulnerable brain regions in both patient groups.

AD is generally associated with widespread brain atrophy that initiates in the transentorhinal and entorhinal cortex in the early stages and then spreads to the remaining neocortical areas (Fjell et al., 2015). Neuroimaging studies show that the widespread pattern of neurodegeneration caused by AD in the limbic and neocortical regions correlates closely with cognitive deficits and behavioral patterns that AD patients exhibit. However, determining the early stages of AD pathophysiology still remains a challenge. Recently a comprehensive study based on high-resolution MRI on people with MCI and AD revealed that the earliest signs of AD pathology appeared in the cholinergic cells of the nucleus basalis of Meynert (NbM) in the basal forebrain (Schmitz et al., 2016).

Interestingly, neuroimaging studies of brains in individuals with T2DM also show structural alterations that resemble those seen in AD patients. In an elegant study conducted by Moran et al. 350 people with T2DM and 363 control individuals were assessed for cognitive functions with an MRI scan to identify the regional distribution of brain atrophy to identify the causes of cognitive impairment in T2DM patients (Beckett et al., 2015; Moran et al., 2015). The investigators found that T2DM was associated with more cerebral infarcts and reduced volumes of gray matter, white matter, and hippocampus compared to non-diabetic individuals. It was further observed that in people with T2DM, gray matter loss was most prominent in medial temporal, anterior, cingulate, and medial frontal lobes—the regions maximally vulnerable to AD. Moreover, cognitive functions, and in particular visuo-spatial skills, were markedly affected in the T2DM group. Another study by Roberts et al. examined the associations of T2DM with imaging biomarkers and cognitive abilities in 1,437 elderly individuals without dementia (Roberts et al., 2014). They found that midlife T2DM was associated with reduced hippocampal and whole brain volumes strongly indicating decline of cognitive functions later in life. Wennberg et al. conducted a study on 233 cognitively normal individuals who were assessed for fasting blood glucose and cortical thickness measurements by MRI (Wennberg et al., 2016). This study showed that higher blood glucose was associated with

reduced average thickness in the AD vulnerable regions. Based on these observations, the authors conclude that the brain atrophy in T2DM, evident from imaging studies, bears striking resemblance to that seen in preclinical AD.


Shared Pathophysiology Between AD and T2DM

PET and MRI studies show marked impairment of glucose and energy metabolism in both T2DM and AD (Umegaki, 2014). In addition, amyloidogenesis remains a salient feature in both these diseases. Extracellular β -amyloid plaques form one of the characteristic features of AD. Likewise, deposits of amyloidogenic peptide (IAPP) are detected in the pancreatic islets of Langerhans of T2DM patients (Haataja et al., 2008). Interestingly, diabetic mice overexpressing IAPP develop oligomers and fibrils with more severe diabetic trait similar to AD mouse models that overexpress APP (Marzban et al., 2003). Advanced glycation end products (AGE) and their receptors (RAGE) accumulate in the sites of diabetic complications such as kidney, retina, and atherosclerotic plaques under conditions of ER and oxidative stress (Nowotny et al., 2015). Similarly, glycated products of A β and tau form in transgenic AD models as well as in post-mortem brains of AD patients under similar stress conditions and form an important component of neurofibrillary tangles (Schedin-Weiss et al., 2014). Moreover, additional traits of synaptic dysfunction, activation of the inflammatory response pathways and impairment of autophagy are pathological features common to both AD and T2DM (De Felice and Ferreira, 2014; Carvalho et al., 2015).

The first section of this review will discuss the impact of brain insulin resistance evident in T2DM on the two hallmarks of AD, A β , and tau and describe the possible mechanisms that interconnect AD and T2DM in the areas of synaptic dysfunction, inflammation, and autophagic impairment (**Figure 1**).

ALZHEIMER'S DISEASE: INSULIN RESISTANCE IN THE BRAIN

Brain insulin resistance is a significant, yet often over-looked feature of AD (De Felice et al., 2014). Insulin released from the pancreas is transported to the brain via the blood brain barrier using a receptor-mediated mechanism. While the crucial role of insulin response in the peripheral tissues is well documented, there are very few reports about the function of insulin in the central nervous system. The insulin levels in human and rodent brain tissue are relatively low compared to circulating levels (Talbot, 2014). There are some reports about reduced insulin levels in the AD brains; however, this finding was not significant compared to the age-matched controls (Stanley et al., 2016). Recently several studies have reported reductions of insulin mRNA in AD, however the results of *de novo* insulin synthesis have been controversial (Blázquez et al., 2014). Thus, it is hypothesized that majority of brain insulin comes from the peripheral tissues and the role of insulin produced in the CNS is still unclear.



Although, the brain was initially considered a non-insulin target organ; several studies indicate the widespread distribution of insulin receptors (IR) in the brain particularly in the olfactory bulb, cortex, hippocampus, and hypothalamus indicating an intricate “neuroregulatory” role for insulin (Kim and Feldman, 2015). IRs in the brain are enriched in neurons compared to glia, and concentrated at the synapse. However, contrary to the IRs found in the peripheral tissues, the primary function of brain IRs is not glucose transport and metabolism. Instead, the brain IRs perform diverse functions including homeostatic regulation, modulation of synaptic plasticity, and neurotransmission and age related neurodegeneration (Plum et al., 2005).

The crucial function of glucose uptake and utilization in the brain is carried out by Glucose transporter 4 (GLUT4). Insulin activates GLUT4 gene expression and translocation from the cytosol to the plasma membrane to regulate glucose homeostasis in the brain and maintains energy requirements for a variety neuronal functions (Chiang et al., 2001; Reno et al., 2017).

Insulin Signaling in the Brain

A large number of recent studies provide compelling evidence that deficits in insulin signaling, arising due to insulin resistance, occurs in AD (Talbot et al., 2012; Mullins et al., 2017). FDG-PET studies of the brains of “early stage” AD patients have demonstrated reduced glucose uptake leading Suzanne de la

Monte and colleagues to classify AD as “Type 3 Diabetes” (de la Monte and Wands, 2008).

In the brain, insulin and IGF signaling mechanisms are crucial for maintaining synaptic plasticity and cognitive functions (Boucher et al., 2014). Once insulin binds to the IR, it is activated by auto-phosphorylation of several tyrosine residues which in turn activates insulin receptor substrates 1 (IRS-1) and 2 that initiate a host of downstream signaling cascades through phosphatidylinositol-3-kinase (PI3K) (Figure 2). PI3K then activates AKT, which phosphorylates GSK-3β at serine 9 residue thereby inhibiting its activity and resulting in glycogen synthesis (Avila et al., 2012). There are numerous reports that GSK-3β is one of the key tau kinases playing a central role in AD pathogenesis (Chatterjee et al., 2009; Hernandez et al., 2013). Physiologically GSK-3β is involved in maintaining synaptic plasticity and regulates NMDA receptor-mediated long-term potentiation (LTP) and long-term depression (LTD) effects at the synapses (Bradley et al., 2012). In the disease state however, GSK-3β is hyperactive and phosphorylates tau at pathological epitopes. Hyperphosphorylated tau then aggregates to form neurofibrillary tangles (Avila et al., 2010). GSK-3β is also a key mediator of apoptosis suggesting that it might activate neuronal loss in degenerative diseases with increased production of Aβ (Qu et al., 2014). Emerging data also shows that PI3K/AKT pathway regulates synaptic plasticity by stimulating excitatory and

inhibitory cell membrane receptors, enhances neurotransmitter activities and increases cortical glucose metabolism in the brain regions that are important for learning and memory (Farrar et al., 2005). In parallel, insulin activates the MAPK pathways leading to Ras activation at the plasma membrane and the sequential activation of Raf, MEK, and ERK (Zhang et al., 2011) (**Figure 2**). Although a direct role of the components of the MAPK pathway in mediating AD pathology has not yet been deciphered, recent reports indicate that ERK plays a crucial role in synapse formation and learning/memory functions implying that it may have additional neuroprotective functions (Thiels and Klann, 2001). Apart from PI3K/AKT and Ras/Raf/MAPK pathways, less well-defined roles in AD pathogenesis are played by mammalian target of rapamycin (mTOR) and its downstream targets that regulate neuronal survival and nutrient sensing. mTOR regulates protein synthesis by phosphorylating the key substrates of the translational machinery namely the eukaryotic initiation factor 4E-binding protein (4E-BP1) and p70S6 kinase (S6K1). Rapamycin inhibits mTOR *in vivo* and halts cellular growth and proliferation (Showkat et al., 2014).

It is hypothesized that in an insulin-resistant state these downstream signaling pathways are compromised leading to increased levels of A β oligomers and hyperphosphorylated tau not only due to a dysregulation of the downstream kinases but also due to an impairment of autophagic clearance that arises as a result of imbalance of the mTOR and autophagy pathways. Autophagic dysfunction, which is an emerging feature of AD causes the progressive accumulation of toxic proteins and eventually leads to neuronal death (Orr and Oddo, 2013).

From the epidemiological and brain neuroimaging studies it is evident that insulin and IGF signaling pathways are important for preservation and maintenance of learning and memory processes that are compromised in AD. Supporting this, intranasal insulin administration improves learning and memory functions in AD patients, emphasizing the shared pathophysiology in both diseases (Benedict et al., 2007).

CROSSTALK OF T2DM AND A β PATHOLOGY IN AD

One of the hallmarks of AD pathology is the formation of extracellular amyloid plaques composed of insoluble deposits of amyloid- β protein aggregates. A β is generated from the proteolytic cleavage of amyloid precursor protein (APP) by a sequence of enzymatic reactions from BACE-1, β and γ -secretase complex (Vassar, 2004). It is hypothesized that lower concentration of A β remains in the soluble form and subject to clearance after degradation, while higher concentrations aggregate into insoluble plaques that are resistant to degradation (Esparza et al., 2016). While there is no evidence that AD brains secrete more soluble A β than normal brains, a recent body of evidence suggests that an increased accumulation of insoluble A β plaques arise due to impaired clearance of A β protein (Wildsmith et al., 2013).

Impact of Hyperinsulinemia on A β

Emerging studies indicate that hyperinsulinemia may confer risk of AD by modulating A β toxicity. The enzyme responsible for degrading the A β protein is Insulin Degrading Enzyme (IDE), which also degrades insulin (Qiu and Folstein, 2006). In T2DM, peripheral hyperinsulinemia increases the concentration of insulin which acts as a competitive substrate for IDE and inhibits the degradation of A β that gradually accumulates to form insoluble plaques. IDE has previously been identified as the primary regulator of A β in both neurons and glia (Son et al., 2016). In a recent study Farris et al. demonstrated that homozygous deletions of IDE gene (IDE $-/-$) in mice, resulted in 50% decrease in A β clearance in brain homogenates and primary neuronal cultures (Farris et al., 2003). The IDE depleted mice exhibited increased cerebral accumulation of endogenous A β , in addition to the hyperinsulinemia and glucose intolerance that characterize T2DM. Hyperinsulinemia also affects APP transport. *In vitro* studies by Gasparini et al. demonstrated that in β APP overexpressing N2a cells and primary neuronal cultures, insulin decreases the intracellular accumulation of A β by promoting the transport of β APP/A β from the trans-golgi network to the plasma membrane (Gasparini et al., 2001). Thus, in addition to inhibiting the degradation of A β by IDE, insulin increases the concentration of extracellular A β by modulating the trafficking of APP. The investigators also show the involvement of receptor tyrosine kinase/mitogen-activated protein (MAP) kinase pathway in regulating intracellular A β transport (Matos et al., 2008).

Impact of Insulin Resistance on A β

Studies by Cheignon et al. have shown that inhibition of PI3K leads to reduced A β production (Cheignon et al., 2018). When they crossed neuron specific IR knockout mice to APP overexpressing Tg2576 transgenic mice, this study found that loss of insulin signaling in the brain reduced production of A β and amyloid plaque deposits. However, the decrease of A β burden was not sufficient to rescue the mortality observed in these transgenic mice. Nevertheless, this data provides strong evidence that IRS signaling plays an important role in modulating the A β deposition.

Investigating the effect of diet-induced insulin resistance on amyloidosis in Tg2576 AD transgenic mouse models, Ho et al. found that the animals displayed the first signs of memory deficits only at 6 months of age. These animals also maintained normal circulating insulin levels and glucose metabolism till they were 13 months old when there was evidence of plasma hyperinsulinemia. Interestingly, despite high production of A β and senile plaques in the brain, these mice showed no evidence of neuronal death and neurofibrillary tangles. However when these mice were reared on a high fat diet they developed non-insulin dependent diabetes mellitus, that led to increased production of A β 40 and A β 42, higher activation of γ -secretase as well as GSK-3 α and GSK-3 β . Biochemical evidence has shown that these mice displayed lower PI3K and AKT activation signals denoting insulin resistance with impaired learning and memory functions (Ho et al., 2004; Chouliaras et al., 2010).




FIGURE 2 | Neuronal signaling mechanisms in a state of insulin sensitivity and insulin resistance. In the insulin sensitive state insulin binds to the receptor and activates the insulin receptor tyrosine kinase that initiates a cascade of phosphorylation events at the IRS/PI3K/AKT and Ras/Raf/ERK pathways. AKT phosphorylates GSK-3 β at the inhibitory serine 9 residue and allows tau to maintain its physiological function of binding to microtubules and facilitates normal axonal transport of neuronal vesicles. In a state of insulin resistance, GSK-3 β is activated by phosphorylation at Tyrosine 216 residue and hyperphosphorylates tau at pathological epitopes. Hyperphosphorylated tau then detaches from the microtubules and aggregates to form neurofibrillary tangles. Likewise, in the presence of excess insulin, the insulin degrading enzyme (IDE) is unable to degrade and facilitate clearance of A β oligomers that act as a competitive substrate for insulin. Thus, insulin resistance facilitates the formation of both A β and tau oligomers.

Impact of Hyperglycemia on A β

Elevated plasma glucose levels are a common pathological feature of T2DM affected individuals. A compelling link between glucose metabolism and AD was established in a study conducted in transgenic APP/PS1 murine models (Macauley et al., 2015). The researchers observed that the induction of acute hyperglycaemia in young mice increased the production of A β and lactate in hippocampal interstitial fluid and this was associated with an increase in neuronal activity (Minkeviciene et al., 2009). These effects worsened in aged AD mice with increased A β plaque pathology. These findings suggest that transient hyperglycemia associated with T2DM can initiate the formation of A β plaques. In this study, the authors also show that hippocampal ATP sensitive potassium (KATP) channels act as metabolic sensors of the alterations in glucose concentration with changes in electrical activity and extracellular A β deposition.

In addition, aberrant glucose metabolism activates glycation reactions that leads to the formation of advanced glycated end products (AGE). Elevated AGE levels in the circulation and in the brain have been associated with cognitive impairments in AD patients (Li et al., 2013). Numerous studies show that there is an increased accumulation of AGE in the brain of diabetic rats implying that AGE products impair the removal of A β 42 and induce A β aggregation in the brain (Moreira et al., 2003).

AGEs enhance the expression of its receptor RAGE, which is also a presumed receptor for A β (Srikanth et al., 2011). Recent reports have shown increased RAGE expression in the astrocytes and microglia of AD brains (Solito and Sastre, 2012). Also, studies on triple transgenic model of AD (3xTg AD) expressing 3 dementia-related transgenes, namely APPSWE, PS1M146V, and tauP301L and raised on high-fat diet as well as STZ-induced diabetic APP/PS1 dual transgenic AD mice demonstrate increased RAGE expression in neurons and astrocytes with an activation of pro-inflammatory cytokines and enhanced decline of cognitive and memory functions (Choi et al., 2014). As a consequence of the damaging inflammatory responses, RAGE causes vascular complications in AD and T2DM. Neuron-specific overexpression of dominant negative RAGE results in restoration of cognitive functions and stops the progression of neuropathological changes in AD mice (Liu L. P. et al., 2009). Treatment of transgenic AD mice with RAGE inhibitor decreases microglial activation and A β production (Crisuolo et al., 2017). Interestingly, soluble form of RAGE (sRAGE) is neuroprotective (Deane et al., 2012; Lee and Park, 2013).

O-GlcNAcylation is a nucleocytoplasmic post-translational modification that occurs abundantly in neurons and protects against A β -mediated neuronal toxicity. Recent studies show that a moderate level of O-GlcNAcylation is neuroprotective

and decreases formation of A β production by inhibiting γ -secretase activity (Hanover and Wang, 2013). Insulin resistance and hyperglycemia increases the level of O-GlcNAcylation but the amelioration of γ -secretase activity is counterbalanced by the accumulation of glycosylated end products that are ultimately toxic to neurons.

Impact of Dyslipidemia on A β

Insulin plays a crucial role in lipid metabolism and impairments in insulin signaling lead to increased lipolysis and elevated synthesis of free fatty acids (FFA) (Wilson and Binder, 1997). Human brain produces approximately 30% of total body cholesterol, hence slight alterations in lipid metabolism can have profound effects on cognitive function. Recent studies show that the interaction between cholesterol and APP in the plasma membrane is necessary for A β synthesis and clearance. Tg2576 AD mice raised on a diet supplemented with high fat and high cholesterol displayed increased production of A β . When these animals were treated with cholesterol lowering drugs the brain amyloid levels were reduced by more than 2-fold (Nizari et al., 2016).

Impact of A β Oligomers on Insulin Resistance

Soluble oligomers of A β 42 have been shown to be the most toxic species to the neurons. In the brains of AD patients with MCI, A β oligomers have been shown to correlate with rapid cognitive decline (Ferreira et al., 2015). Also, in the brain and CSF of AD patients the level of soluble oligomers ranging from trimer to 24-mer or higher is significantly elevated when compared to levels found in non-demented controls (Jimenez et al., 2014). Studies in human APP overexpressing Tg2576 AD mice show that the onset of memory deficits correlate with production of soluble A β oligomers. Small oligomers of A β , particularly dimers and trimers that are formed within the neurons *in vitro* are secreted into conditioned medium. The treatment of rat hippocampal slices or live animals with these oligomers showed potent LTP defects and cognitive deficits (Puzzo et al., 2017). Similarly, synaptotoxicity is observed when soluble A β oligomers isolated from the brains and CSF of AD patients are applied to brain tissue slices or live animals (Minkeviciene et al., 2009). These, inhibitory effects are blocked by A β antibodies and γ -secretase inhibitors (Goure et al., 2014). This LTP blockage is also restored by treatment with 1 μ M insulin (Sakono and Zako, 2010). These observations were confirmed by other investigators who demonstrated that A β 42 oligomers were more potent in blocking LTP than monomers and this effect was rescued by insulin by preventing A β oligomerization (Selkoe, 2008; Mucke and Selkoe, 2012).

Recent evidence indicates an intimate connection between brain insulin resistance and the formation of A β oligomers. In a study by Zhao et al. the scientists found that the treatment of primary hippocampal neurons by soluble A β oligomers results in a profound loss of insulin receptors from the neuronal surface. In addition, A β oligomers were found to increase the AKT phosphorylation at Serine-473 residue which results in insulin resistance (Zhao and Townsend, 2009). In addition, A β oligomers inhibit insulin signaling by phosphorylating IRS1 at inhibitory

serine residues via the JNK/TNF alpha pathway (De Felice et al., 2009). Conversely, treating AD patients and transgenic animals with intranasal insulin lowers the concentration of soluble A β and improves memory (De Felice et al., 2009). A β -induced insulin resistance was also observed in the Familial AD (5XFAD) transgenic mouse models that overexpress high levels of mutant APP and PS1 and display severe amyloid pathology since 2 months of age (Mosconi et al., 2008).

Overall these studies demonstrate a strong impact of insulin resistance, hyperglycemia, dyslipidemia, and other hallmarks of T2DM on the pathological effects of A β amyloidogenesis as observed in AD.

CROSSTALK OF T2DM AND TAU PATHOLOGY IN AD

The traditional physiological function of tau protein is to promote assembly and stabilization of microtubules, though newer, atypical functions are now being reported (Sotiropoulos et al., 2017). There are about 80 Ser/Thr and 5 Tyr phosphorylation sites on tau that are phosphorylated by the key tau kinases namely GSK-3 β , MARK/PAR1, and CDK5 (Stoothoff and Johnson, 2005; Chatterjee et al., 2009). While in the normal brain, tau contains 2–3 moles of phosphate/mole of tau protein; in abnormal situations as seen in AD brains and other tauopathies, tau becomes hyperphosphorylated with 6–9 moles of phosphate/mole of tau and aggregates to form intracellular neurofibrillary tangles, one of the pathological hallmarks of AD (Iqbal et al., 2010).

A wealth of emerging studies in recent years indicate that the density of the neurofibrillary tau tangles deposited at the neocortex of the brains of MCI patients correlated more strongly with the severity of the disease (Bierer et al., 1995; Nelson et al., 2012). This study showed that learning and memory defects were more acute in patients with higher accumulation of the tangles in the temporal lobe which is the brain region associated with learning and memory. Thus, the post translational modifications of tau (hyperphosphorylation, truncation, acetylation, and glycation) and associated cellular and biochemical changes that cause these abnormal structural alterations are of potential interest for the development of tau targeted therapeutic studies.

Two of the important features of T2DM namely insulin resistance and hyperglycemia are able to influence post translational modifications of tau and exacerbate tau pathology, discussed below:

Impact of Insulin Resistance on Tau Kinases and Phosphatases

Under physiological conditions, a host of kinases and phosphatases regulate the intricate balance between tau phosphorylation and dephosphorylation to maintain neuronal homeostasis. Several protein kinases such as GSK-3 β , CDK5, MARK, PKA, PKB/AKT, and MAPK including ERK1/2, c-JUN N terminal kinase (JNK) and p38 are the important kinases that phosphorylate tau (Avila, 2008; Gómez-Sintes et al., 2011).

Among these kinases, AKT and GSK-3 β are located downstream of one arm of the insulin signaling pathway while components of the MAPK pathway lie downstream of the other arm (Fröjdö et al., 2009). AKT phosphorylates GSK-3 β at the inhibitory Serine-9 residue and maintains GSK-3 β in the inactive form. However, under conditions of insulin resistance, GSK-3 β is converted to its active form by phosphorylation at Tyrosine-216 residue. Active GSK-3 β then hyperphosphorylates tau to generate the pathological epitopes AT8, AT100, and PHF1 which make up the pre-tangles and NFTs in the AD brains (Clodfelder-Miller et al., 2005).

Several other studies have found that p70S6 ribosomal protein kinase—an AKT/mTOR substrate can directly phosphorylate tau and upregulate its synthesis through phosphorylation of S6 (Yoon, 2017).

These key pathways, namely PI3K/AKT, MAPK, and mTOR/p70S6K are regulated by insulin binding to the insulin receptor and trigger downstream phosphorylation events (Fröjdö et al., 2009). Thus, it is not surprising that in an insulin resistant state, insulin is unable to activate these pathways thereby disrupting physiological tau phosphorylation. Additionally, in diabetic brains p38 and JNK activation can cause insulin resistance by inhibiting the insulin receptor substrate and trigger tau hyperphosphorylation and pathological events (Wu et al., 2013).

Tau is also regulated by phosphatases especially PP2A that dephosphorylates it at crucial residues Thr205, Thr212, and Ser 262 that are phospho-epitopes of GSK-3 β and MARK/PAR-1. In addition, PP2A dephosphorylates the kinases GSK-3 β and p70S6K to maintain tau phosphorylation at a physiological level (Gratuze et al., 2017). Interestingly, several researchers have shown a downregulation of PP2A in both T1DM and T2DM mice suggesting that insulin resistance might exacerbate tau phosphorylation by downregulating PP2A (Qu et al., 2011; Jung et al., 2013).

The impact of isolated CNS-specific insulin resistance on tau phosphorylation was investigated *in vivo* by Schubert et al. using NIRKO mice where the brain/neuron specific IR gene was conditionally inactivated. They found that NIRKO mice displayed a complete loss of insulin-mediated PI3K/AKT signaling resulting in reduced phosphorylation of GSK-3 β at Serine-9 and increased tau phosphorylation. However, these animals did not exhibit any change in survival or learning and memory defects or basal brain glucose metabolism (Schubert et al., 2004). In another study modeling peripheral insulin resistance in IRS2 knock out (KO) mice Schubert and colleagues show that neurofibrillary tangles composed of hyperphosphorylated tau aggregates accumulate in the hippocampus of IRS2 KO mice, revealing a direct molecular link between diabetes and Alzheimer's disease (Schubert et al., 2003). Likewise, Cheng et al. in IGF KO mouse brains displayed increased tau phosphorylation at Ser-396 and Ser-202 residues both of which are implicated in neurodegeneration (Cheng et al., 2005). In STZ-induced Type 1 diabetic mouse models, Planel and colleagues observed a robust increase in tau hyperphosphorylation that prevented tau from binding to microtubules (Planel et al., 2007). The scientists further observed

that a downregulation in the activity of PP2A in these transgenic models exacerbated tau pathology. Similarly, Yazici and colleagues administered STZ to induce diabetes in pR5 mice expressing P301L mutation. Compared to non-transgenic controls, the pR5 mice displayed massive tau hyper-phosphorylation with the formation of neurofibrillary tangles by 6 months of age (Ke et al., 2009). In addition, other studies show that treatment of STZ-induced diabetic mice with GSK-3 β inhibitors improves learning and memory functions (King et al., 2013). All these studies provide compelling evidence that both Type 1 and Type 2 diabetes can accelerate onset and disease progression in individuals with a predisposition to developing tau pathology.

Impact of Insulin Resistance on Tau Cleavage

In addition to hyperphosphorylation, another abnormal post-translational modification of tau is truncation. Tau is cleaved by a host of proteolytic enzymes including caspases, calpains, thrombins, and puromycin-sensitive amino peptidase. These truncated tau fragments lack both N terminal and C terminal fragments and form the core component of NFTs (Karsten et al., 2006; Zilka et al., 2006).

In AD brains, caspases are activated causing tau protein to be cleaved at several residues. The C-terminal cleavage of tau by caspase-3 gives rise to Asp421 residue that has a higher propensity of aggregation and is found to be associated with neurofibrillary pathology in AD brains. The presence of Asp421 truncated tau in the neurofibrillary aggregates observed in the neurons of double transgenic mice (Tet/GSK-3 β /VLW) and in P301S mouse models of tauopathy indicates that the formation of Asp421 cleavage product is an important step toward formation and maturation of tau aggregates (Basurto-Islas et al., 2008; Gendron and Petrucelli, 2009; Gómez-Sintes et al., 2011).

Diabetes has been known to stimulate apoptosis by the activation of caspase-3 in affected tissues (Savu et al., 2013). Using an animal model of T2DM, Kim et al. in their studies demonstrated an increased level of tau phosphorylation and cleavage in the brains of db/db mice which are models for diabetic dyslipidemia (Kim B. et al., 2013). Feldman and colleagues found that hyperglycemia promotes tau cleavage by activation of caspases (Kim et al., 2009). Thus, these studies demonstrate that T2DM enhances the formation of tau truncated fragments by caspase activation that contribute toward an increased risk of AD in diabetic patients.

Impact of Hyperglycemia on Other Posttranslational Modifications of Tau

Acetylation is a post translational modification in which the acetyl group from acetyl CoA is reversibly transferred to lysine ϵ amino group in the tau protein. This process is modulated by acetyltransferases and deacetylases (Cook et al., 2014). Cohen et al. observed that tau acetylation at the key lysine residues at K/163/280/281/369 was crucial for tau-microtubule binding interactions and microtubule stabilization. Using cellular and transgenic mouse models as well as human brains from a wide spectrum of tauopathies this group has demonstrated that tau

acetylation disrupts the tau-microtubule binding interactions and promotes pathological tau aggregation. This group further demonstrated that acetylated tau was associated with the formation of insoluble tau NFTs in tau transgenic mice and human tauopathies indicating “acetylation” as a pathogenic post-translational modification of tau (Cohen et al., 2011).

Protein acetylation plays an important role in intermediary metabolism and metabolic disorders including T2DM. Mass spectrometry on STZ-induced diabetic rats showed high levels of lysine-acetylated proteins in their kidney cells compared to control animals (Kosanam et al., 2014). Also, treatment of murine aorta cells with high glucose or FFA to induce short term diabetes causes increased levels of lysine acetylation (Samuel et al., 2017). Although, there are very few reports, aberrant acetylation of tau in T2DM may interfere with the physiological functions of microtubule binding and assembly predisposing cytoplasmic tau toward the formation of aggregates (Irwin et al., 2013; Trzeciakiewicz et al., 2017).

Glycosylation involves the attachment of oligosaccharide moieties to proteins and lipids. O-glycosylation is the linkage of sugar residues to the hydroxyl groups of Serine or Threonine residues while N-glycosylation involves attaching the sugar moieties to the amine group of the asparagine residues in proteins (Wang et al., 1996). Impaired O-GlcNAc cycling is implicated in AD. In *post-mortem* AD brains Zhu et al. have demonstrated a significant decrease of O-GlcNAc glycosylation of tau proteins compared to controls (Zhu et al., 2014). Other studies from AD patients show hyperphosphorylated but hypo-O-GlcNAc glycosylated tau implying that phosphorylation and O-glycosylation at Serine and Threonine residues act in opposition (Wang et al., 1996; Iqbal et al., 2010). *In vitro* studies in NMR and Mass spectrometry analysis by Smet-Nocca et al. demonstrated that tau hyper phosphorylation at residues Ser-396 and Ser-404 were reduced by O-glycosylation at Ser-400 (Smet-Nocca et al., 2011). Treatment of mouse models of AD with OGA inhibitor Thiamet-G (that increases the levels of O-GlcNAcylation of tau) was found to decrease the levels of NFT burden and pathological tau species and slow down disease progression (Robertson et al., 2004; Gong et al., 2005; Yuzwa et al., 2012). However, it is interesting that Thiamet-G decreases tau phosphorylation over a short period of time and prolonged OGA inhibition has no effect on phosphorylation. This is probably due to cellular adaptability over time. Compared to O-glycosylation, *in vitro* studies show that N-glycosylated tau isolated from AD brain promotes tau hyperphosphorylation (Liu Y. et al., 2009). Taken together these studies demonstrate that glycosylation exerts varying effects on tau hyperphosphorylation.

Although it is still speculative, it has been hypothesized that abnormal glucose metabolism in the brain induced by T2DM may lead to decreased brain O-GlcNAc levels. This reflects a failure in the neuroprotective mechanism in the brain and triggers the cascade of tau pathology enabling disease progression.

Impact of Tau on Insulin Resistance

While insulin resistance stimulates tau hyperphosphorylation and aggregation, in a recent study Rodriguez-Rodriguez and colleagues have shown that pathological alterations in tau

(hyperphosphorylation and aggregation) accumulates insulin. In this study, the researchers have shown that insulin accumulates in the sarcosyl-insoluble fractions of the AD brain. Moreover, the researchers found increased accumulation of insulin *in vivo* in the brains of tau overexpressing P301S mice and SHSY5Y cells as well as in okadaic acid treated primary neuronal cultures. Both the cells and primary neurons demonstrated increased insulin uptake from the surroundings that eventually led to insulin resistance (Rodriguez-Rodriguez et al., 2017). Another study shows impaired insulin sensitivity in hippocampal slices from tau KO mice compared to litter-mate controls (Marciniak et al., 2017).

These studies suggest a complex relationship between tau and insulin resistance as it is evident that not only insulin resistance can exacerbate tau pathology but pathological tau phosphorylation or absence of tau can affect neuronal insulin resistance.

SYNAPTIC DYSFUNCTIONS AT THE CROSSROADS OF AD AND T2DM

There is widespread neuronal loss and atrophy of the cortex and hippocampus in the brains of AD patients (Sheng et al., 2012). The cognitive failure in AD patients is accompanied by loss in synapses and neuronal cell death with a marked reduction in brain volumes particularly at the entorhinal cortex and hippocampus. Although plaques and tangles characterize the neuropathological features of AD, the closest correlation to the severity of disease progression is the synapse loss that occurs in the disease. There are conflicting reports as to whether the amyloid plaques or NFTs correlate more strongly with disease progression. Some scientists have reported that the spatiotemporal signature of NFTs of tau correlate more severely with the disease pathology (Nelson et al., 2012; Horvath et al., 2013). However, investigating the “neurodegenerative triad” Tackenberg et al. have shown that the loss of dendritic spines and LTP that occurs early in the disease is mediated by A β while the late stage cell death mediated by NMDAR requires tau phosphorylation (Tackenberg and Brandt, 2009).

Alterations in synaptic transmission and plasticity are also observed in the hippocampus of diabetic animal models including depletion of synaptic vesicles at presynaptic sites and changes of AMPA and NMDA receptors at the postsynaptic sites. Moreover, diabetes affected the synthesis and release of both inhibitory and excitatory neurotransmitters (Gaspar et al., 2016). All of these factors have the potential to activate synaptic dysfunction and widespread neuronal loss thereby predisposing the diabetic brain to AD. In this section the impact of T2DM on A β and tau mediated dysfunctions will be elaborated.

Synaptic Dysfunctions in AD

Recent studies indicate that cognitive ability in AD patients is closely related to the alterations of the density of the presynaptic glutamatergic boutons with an elevation of the glutamatergic synapses in MCI patients and a gradual depletion of the boutons with the progression of AD (Bell et al., 2007).

A β and Synaptic Dysfunction

There are numerous reports that show A β oligomers can cause synaptic dysfunction and toxicity (LaFerla and Oddo, 2005; Shankar and Walsh, 2009). Under physiological conditions, low concentration of monomeric A β is essential for maintaining synaptic plasticity and neuronal survival with the improvement of cognitive abilities. Conversely, in the disease state higher concentration of A β together with aging causes synaptic dysfunction followed by neuronal loss as seen in AD. Recent studies show that APP and BACE1 KO mice display pronounced defects in LTP and memory functions (Tyan et al., 2012). Puzzo et al. showed that the treatment of mouse brain hippocampal slices with low concentrations (200 picomoles) of synthetic A β 42 monomers and oligomers increased the LTP. This study suggests that LTP is mediated by α 7-nicotinic acetylcholine receptors indicating a presynaptic role of A β . Likewise, treatment with nanomolar concentration of A β produced synaptic depression. This indicates that an optimal level of A β is needed for synaptic transmission (Puzzo et al., 2017).

Elevated levels of A β impairs glutamatergic transmission by decreasing the number of AMPA and NMDA receptors on the surface of the neurons. Moreover, increased concentration of A β results in the internalization of NMDA receptors enhancing LTD at the synapses. LTD causes a significant loss of dendritic spines that is associated with early symptoms of AD and disease progression (Palop and Mucke, 2010). EEG recording from cortical and hippocampal networks in human APP overexpressing mouse models shows that high levels of A β oligomers elicits epileptic and nonconvulsive seizures (LaFerla and Oddo, 2005). Consistent with these findings, *in vivo* calcium imaging of cortical circuits shows that double transgenic (hAPP/PS1) mice have a greater proportion of hyperactive and hypoactive neurons than nontransgenic control (Palop and Mucke, 2010; Puzzo et al., 2017). AD transgenic mice showed an increased neuronal activity in the hippocampal regions before the formation of insoluble amyloid plaques. On treatment with a γ -secretase inhibitor, soluble A β levels were reduced and the neuronal activity decreased implying that this effect was a soluble A β -dependent effect (Busche et al., 2012). Although the mechanisms are not completely elucidated, these studies suggest that A β -dependent effects on synaptic plasticity and neurotransmission are tightly controlled by the activation of α 7-nicotinic acetylcholine receptors or NMDARs and involves downstream effector components including p38 MAPK and GSK-3 β (Baglietto-Vargas et al., 2016).

T2DM may trigger A β -mediated synaptic dysfunction in multiple ways. Hyperinsulinemia in T2DM promotes the formation of A β oligomers that cause synaptotoxicity. Investigators have shown that when A β oligomers are applied *in vitro* to rat hippocampal slices or *in vivo* to live animals they blocked LTP and inhibited memory formation (Busche et al., 2012). Interestingly, this effect is overcome by 1 μ m insulin. A similar result was reported by Li et al. who observed that A β monomers were more effective than A β oligomers in inhibiting LTP and that insulin prevented A β -induced LTP

defects by blocking A β oligomerization (Balducci et al., 2010; Li et al., 2011). Previous studies have shown that A β oligomers are capable of binding to insulin receptors which causes an impairment of receptor functions (Bradley et al., 2012; Uranga et al., 2013). In addition, it has been shown that A β oligomers alter GSK-3 β phosphorylation state and directly impacts the ERK pathway (Magrane et al., 2006; Reddy, 2013).

Tau and Synaptic Dysfunction

Recent research suggests an emerging role of tau at the synapse (Pooler et al., 2014). Physiologically tau is localized primarily in the axons where it binds and regulates microtubule dynamics in a phosphorylation dependent manner (Janning et al., 2014). However, recent isolation and analysis of AD brain-derived synaptoneuroosomes indicate that tau is present in both pre-synaptic and post-synaptic compartments (Tai et al., 2012). There are multiple mechanisms by which tau could mediate synaptic function and neuronal excitability. Recent study has shown that tau binds to the post-synaptic protein complex which includes the PSD-95 through Fyn kinase. The interaction of tau and Fyn appears to be crucial for directing Fyn to the postsynaptic compartments where it can regulate the NMDA receptor by phosphorylating one of its subunits. Abnormal tau phosphorylation can disrupt the tau-Fyn interaction and affect postsynaptic receptor targeting (Haass and Mandelkow, 2010). Thus, neurons from conditionally overexpressing P301L tau mice display impaired targeting of excitatory glutamate receptors to dendritic spines. In addition, biochemical analysis of the synaptosomes from these mice display a marked decrease in the levels of synaptic markers (PSD95, Synapsin, NMDAR1, and GluR1) implying that the loss of functional synapses plays an important role in maintaining postsynaptic integrity (Katsuse et al., 2006; Spires-Jones and Hyman, 2014). Electron microscopy of NFT-carrying motor neurons in P301L mice revealed a significant decrease in the number and size of synaptic boutons compared to nontransgenic controls. These studies point out that loss of synapses occur during neurodegeneration. Evidence for tau involvement in regulating neuronal excitability comes from a study in which a reduction in tau levels reduced hyperexcitability in a mouse model of seizure (Holth et al., 2013; Guerrero-Muñoz et al., 2015). Other studies have found that neurons isolated from transgenic Tg4510 mice overexpressing 0N4R P301L mutation were more excitable than neurons from nontransgenic mice (Kopeikina et al., 2013). However, it is worth noting that the animal models mostly express mutant tau protein and therefore could be more representative of FTDP-17 cases than AD.

Although there are fewer reports, glucotoxicity in T1 and T2DM are capable of influencing tau-mediated synaptic impairments. Investigators have shown synaptic defects and cognitive impairments in STZ-induced diabetic models, where genetically ablating tau ameliorated cognitive defects. (Abbondante et al., 2014). Using a mouse model of tauopathy, scientists have observed that under glucose-deprived conditions as observed in hypometabolic AD brains, transgenic mice

had impaired memory and reduced LTP accompanied by tau hyperphosphorylation and apoptosis (Lauretti et al., 2017).

Synaptic Dysfunctions in Diabetes That Influence Neurodegeneration

Other than directly influencing A β and tau-mediated synaptic defects, diabetes also affects the synthesis and release of key neurotransmitters that may underlie cognitive defects. For instance under chronic hyperglycemia extracellular brain levels of GABA and glutamate were decreased in STZ-induced diabetic animal models (van Bussel et al., 2016). An imbalance between excitatory and inhibitory neurotransmission impaired the cognitive deficits observed in these animals. Diabetes also affects acetylcholine esterase that plays a crucial role in cognitive processes. Recent studies have shown a reduction of cholinergic transmission in the hippocampus of STZ-induced diabetic animals (Molina et al., 2014). Moreover, in the STZ-induced animals, treatment of hippocampal slices with insulin resulted in a significant decrease in the number of NMDA receptors that consequently affected LTP and decreased postsynaptic densities (van der Heide et al., 2005).

Taken together these results suggest that both Type 1 and Type 2 diabetes are able to directly influence A β and tau-mediated synaptic dysfunctions. In addition, both these subtypes cause an imbalance of neurotransmitter release and alterations in synaptic plasticity that ultimately leads to memory impairments. Hence, synaptic dysfunctions form a shared pathological trait between AD and T2DM.

INFLAMMATION: SHARED PATHOPHYSIOLOGY OF AD AND T2DM

Emerging evidence in recent times points toward a compelling link between inflammation and the pathogenesis of Alzheimer's disease since A β plaques and NFTs colocalize with glial cells (Serrano-Pozo et al., 2011). T2DM disease pathogenesis in particular involves high levels of ER and oxidative stress response that might trigger the inflammatory cascade (Back and Kaufman, 2012). Additionally, misfolded toxic protein species detected in AD and T2DM may generate oxidative stress and activate inflammatory pathways. In this section, we discuss the role of inflammation in AD and T2DM and how this impacts the shared pathophysiology in both these diseases.

Inflammation and AD Pathology

Recently preclinical, genetic, and bioinformatics studies have shown that the immune system activation accompanies AD pathology. The genome wide association studies (GWAS) between AD and rare mutations in the genes encoding triggering receptor expressed on myeloid cells 2 (TREM2) and myeloid cell surface antigen CD33 provide clear evidence that there is a strong linkage between alterations in the immune system and the progression of AD pathology (Griciuc et al., 2013; Ulrich et al., 2017).

Based on the amyloid cascade hypothesis, the A β deposition is followed by immune system activation mediated by glial cells such as microglia and astrocytes. This is supported by electron microscopy studies that show increased accumulation of glial cells surrounding the amyloid plaque deposits in AD brain (Wyss-Coray et al., 2003). However, recent data of cerebrospinal fluid analysis from patients with symptoms of MCI has demonstrated a marked alteration in the inflammatory markers implying their involvement early in the disease pathway (Zotova et al., 2010; Wyss-Coray, 2012). In another significant study, scientists showed that systemic immune challenge elicited by injecting viral mimics of polyriboinosinic-polyribocytidilic acid resulted in "sporadic AD" like features in wild-type mouse models accompanied by A β deposition, tau pathology, microglia activation, and reactive gliosis implying that alterations in the immune system can precede AD pathology and drive the disease itself (Michalovicz et al., 2015). In addition, tissue microarrays from patients with neurodegenerative diseases including AD revealed an upregulation of inflammatory components further suggesting an intimate linkage between inflammatory markers and AD, early in the pathogenic cascade (Sekar et al., 2015).

A β and Inflammation

In AD brains, microglia and astrocytes have been known to accumulate around neuritic plaques and are associated with the tissue damages that occur in AD. A β oligomers and fibrils are capable of binding to receptors expressed by microglia including CD14, CD36, CD47, a β 1 integrin, RAGE, and Toll-like receptors (TLRs) (Doens and Fernandez, 2014). *In vitro* studies have shown that binding of A β to RAGE receptors, helps guide microglia to A β deposits and this effect is inhibited by anti-RAGE antibodies (Wyss-Coray, 2012). Binding of A β to CD36 or TLR4, on the other hand, results in the production of inflammatory chemokines and cytokines that eventually lead to increased neuronal damage in vulnerable regions of the AD brain (Doens and Fernandez, 2014). Besides the secretion of inflammatory cytokines, microglia are found to phagocytose soluble A β oligomers via the extracellular proteases such as neprilysin and insulin-degrading enzyme (IDE). However, there are evidences of A β dependent impairment of microglial phagocytosis functions in AD mouse models (Koenigsnecht and Landreth, 2004). Recent studies have shown that microglia isolated from AD transgenic mouse models displayed a substantial reduction in the levels of A β -binding scavenger receptor and A β -degrading enzyme (Zhao et al., 2017). Interestingly, it has been shown that transient depletion of dysfunctional microglia has no impact on A β deposition in an animal model of AD (Morimoto et al., 2011). This is because microglial impairment maybe compensated by inflammatory cytokines such as TNF, IL-1, IL-12, and IL-23 suggesting a negative feedback loop, that might exacerbate the AD pathology (Rubio-Perez and Morillas-Ruiz, 2012). In addition, an upregulation in the levels of inflammatory markers has been demonstrated in animal models of AD or in the brains or CSF of AD patients (Moro et al., 2018).

Recently a huge repertoire of GWAS studies show that structural variants of genes encoding immune receptors TREM2, CD33, and CR1, all of which are expressed in the microglia confer higher risk of AD (Tosto and Reitz, 2013). However, the function of TREM2 deficiency in the progression of AD has been controversial. For instance, while TREM2 deficiency in APP/PS1 mice ameliorated hippocampal A β accumulation; the 5XFAD mice displayed an opposite result. In these mice the A β pathology was found to develop slower than APP/PS1 mice and increased accumulation of hippocampal A β was observed in the absence of TREM2 (Bemiller et al., 2017; Jay et al., 2017). Elevated levels of soluble TREM2 was detected in the CSF of early AD patients suggesting a change in microglial activation in response to neuronal death. Although the exact mechanism still remains to be deciphered, these findings show that impaired TREM2 function plays a vital role in A β -mediated AD pathogenesis.

The transmembrane protein CD33 is another microglial receptor the structural variants of which has led to increased risk of AD. A significant study from *post mortem* AD brains has shown the upregulation of CD33 compared to age-matched controls (Jiang et al., 2014). Conversely, the expression of a CD33 variant, namely the protective CD33 (SNP) rs3865444 was downregulated in AD brains and reduced insoluble A β deposits (Hu et al., 2014; Li et al., 2015b).

Astrocytes too respond to AD pathogenic stimuli by reactive gliosis. In transgenic AD mouse models exhibiting cerebral amyloidosis the activation of astrocytes occur in the early stages of pathogenesis. In these transgenic animals the astrocytes underwent severe atrophy which preceded the A β plaque mediated gliosis (Verkhratsky et al., 2010). Conversely, reducing astrocytes in a transgenic A β overexpressing mouse model ameliorated AD pathology (Garwood et al., 2017). The involvement of astrocytes in neuroinflammation entails increased production of cytokines that either affect the neurons directly or via microglial activation (Van Eldik et al., 2016). For instance, NF κ B-mediated activation of astrocytes release the complement protein C3 that can bind to neuronal C3aR and trigger neuronal damage. Another astrocyte signaling molecule is the soluble CD40 ligand that binds to microglial cell surface receptor. This binding interaction releases pro-inflammatory tumor necrosis alpha (TNF- α) that has been widely reported to contribute to tissue damage in AD (Van Eldik et al., 2016). Astrocytes also play a neuroprotective role. Recent studies have also shown that reactive astrocytes surrounding the A β plaques take up and degrade A β . For instance, in Tg2576 transgenic mice this has been shown to be linked to insulin degrading enzyme (IDE) which plays an important role in A β degradation. Reportedly, A β exposure of IDE enhanced the number of activated astrocytes surrounding the neuritic plaques (Wyss-Coray, 2012). Other studies have shown that treatment of astrocytes with *ex-vivo* A β extracts, increase the secretion of A β degrading enzymes (Wyss-Coray et al., 2003). Thus, the A β pathogenesis in AD may result in alterations of normal astrocyte functions which may be then trigger downstream inflammatory cascades prompting further neuronal damage in AD.

Tau and Inflammation

Although there are fewer reports, *in vitro* studies have shown that microglial cells stimulated by A β or LPS release pro-inflammatory cytokines such as interleukin-1 β and activate tau phosphorylation at the pathological phospho-epitopes via MAPK pathway. This was confirmed by *in vivo* studies in 3xTg mouse model that displays both A β and tau pathologies. When these animals were subjected to high dose of LPS treatment, tau hyperphosphorylation was triggered at the pathological epitopes mediated by GSK-3 β , CDK5, JNK, and MAP kinases (Barron et al., 2017). Several other studies have shown that the activation of the key kinases CDK5 and GSK-3 β by themselves resulted in microglial activation and secretion of IL-1 β implying a close link between tau hyperphosphorylation and pro-inflammatory markers. The gene expression profile analysis in a mouse model of tauopathy (rTg4510) which expresses the P301L mutation, revealed upregulation of pro-inflammatory markers such as complement 4B, glial fibrillary acidic protein (GFAP) and osteopontin (Spp1) on treatment with LPS. This result confirms that neuroinflammation modulates tau pathology in the absence of A β plaques (Wes et al., 2014). In addition, TREM2 levels were decreased in these transgenic mouse models indicating an alteration in microglial functions (Maphis et al., 2015). In this landmark study, Bhaskar et al. showed that LPS treatment of hTau mice expressing all 6 non-mutated tau isoforms enhanced microglial activation and accelerated tau pathology. These mice were deficient in microglia-specific fractalkine receptor (CX3CR1) that caused an exacerbation of tau hyperphosphorylation via p38/MAPK pathway. Further, studies in a P301S mutant human tau transgenic mice demonstrated that these animals displayed synaptic pathology and microgliosis before the onset of tangle formation confirming that microglial activation occurs early in the disease pathway. In this study, the researchers have shown that the immunosuppression of young P301S transgenic mice by FK506 significantly diminished tau pathology and increased their lifespan (Yoshiyama et al., 2007). These studies conclude that neuroinflammation accompanies early AD progression and blocking neuroinflammatory pathways might be beneficial in ameliorating tauopathies.

Hence, anti-inflammatory drugs have been used in clinical trials to prevent disease progression in AD. A study of nonsteroidal anti-inflammatory drugs (NSAIDs) in a Netherlands population (Rotterdam study) showed a significantly decreased risk of AD with increasing use of NSAIDs. In this study the short-term use of NSAID showed a relative risk of 0.95 while a long-term use of 24 months or more showed a relative risk of 0.2 with a confidence interval of 0.05–0.83 (In 't Veld et al., 1998). In a similar study reported in 2011 by Breitner et al. administration of NSAID Naproxen over a period of 2–3 years decreased the incidence of AD. These results were enhanced by measuring a marker of neurodegeneration, CSF ratios of tau to A β 1-42 (Breitner et al., 2011). In contrast, a recent study by Marjerova et al. found that LPS treatment of immortalized microglial cells *in vitro* were capable of removing intracellular and extracellular tau

oligomers by phagocytosis. These observations were validated *in vivo* in C57BL/6 mice. When injected with soluble and insoluble human tau aggregates, these mice displayed active microglial phagocytosis of both tau species (Barron et al., 2017). Thus, the suppression of immune system by anti-inflammatory drugs may not prove beneficial to AD treatment in the long run as these might enhance the spread of tau oligomers across healthy neurons.

Inflammation in Type 2 Diabetes That Influence Neurodegeneration

Type 2 Diabetes has been associated with excess immune system activation, which increases the expression of proinflammatory cytokines especially microglia in the brain. It is noteworthy that Swaroop et al. observed elevated levels of TNF α , IL-1 β , IL-2, and IL-6 in the hippocampus of diabetic animals (Swaroop et al., 2012). Previous studies have shown that incubation of cells with TNF α or high levels of FFA promotes inhibitory phosphorylation of the serine residues of IRS-1. This impairs the ability of IRS-1 to interact with the insulin receptor and generates an insulin-resistant condition capable of triggering A β and tau pathological cascades (Peraldi et al., 1996). It has also been demonstrated that obesity and hyperglycemia in T2DM contributes to ER and mitochondrial stress that generates reactive oxygen species (ROS). Elevated ROS then causes enhanced activation of inflammatory pathways (Kaneto et al., 2010; Back and Kaufman, 2012).

Along with evidences that relate oxidative stress and inflammation to the pathophysiology of diabetes, studies performed in various cellular and animal models suggest NF κ B activation is a key event early in the disease pathobiology and its complications. Several studies have shown that NF- κ B is induced by hyperglycemia and in conditions of neuronal damage (Romeo et al., 2002; Wellen and Hotamisligil, 2005). The activation of NF- κ B is followed by the expression of pro-inflammatory cytokines that jointly trigger brain inflammation and neuronal apoptosis eventually leading to cognitive decline. For instance, in the hippocampus of the STZ-treated rats there is a strong increase of ROS followed by NF- κ B activation (Locke and Anderson, 2011). Activated NF- κ B can induce cytotoxicity, trigger inflammation and promote apoptosis (Jaeschke et al., 2004). In STZ-induced retinopathy rat models, NF- κ B activation has been associated with enhanced expression of caspase 1 (Yin et al., 2017). Recent reports show that NF- κ B might be an important regulator of insulin sensitivity in T2DM by controlling the expression of GLUT2 receptor which is important for glucose secretion and transport in pancreatic beta cells (Patel and Santani, 2009).

Incidentally, the metabolic stresses that promote insulin resistance and T2DM also activate the inflammation and stress-induced kinases I κ B kinase- β (IKK β) and JUN N-terminal kinase (JNK) suggesting that these kinases play an important role in disease pathogenesis. Both JNK and IKK β can phosphorylate the IRS-1 at the inhibitory Serine 307 thereby impairing insulin action (Jaeschke et al., 2004; Morel et al., 2010).

Oxidative stress in insulin resistance generates FFA and AGE products which result in glucotoxicity and impairment of insulin

signaling. These ligands act through Toll-like receptors (TLRs) and receptors for advanced glycation end products (RAGE) that are also activated in neurodegenerative diseases (Ozcan et al., 2004). RAGE especially acts as a putative A β receptor and plays a significant role in AD pathogenesis. It is therefore predicted that the cumulative effect of these stress factors may lead to neuronal apoptosis and brain inflammation, both of which are prominent features of neurodegenerative diseases including AD.

To investigate whether inflammatory pathways act as a potential link between AD and T2DM, Takeda et al. generated a dual model of AD and T2DM by crossing an APP23 transgenic mice that overexpresses human APP to leptin-deficient ob/ob mice or polygenic NSY mice as a model for diabetes. The APP+/ob/ob dual transgenics showed increased levels of amyloid deposition around brain microvessels and enhanced cerebrovascular inflammation even before the manifestation of cerebral amyloid angiopathy. (Takeda et al., 2010). The authors also report an increased levels of RAGE in blood vessels as well as elevated levels of TNF α and IL-6 in the brain microvasculature of these animals. Progressive cognitive deficits and increased cerebrovascular inflammation were also noted in APP+/-NSY dual transgenics raised on high-fat diet compared to NSY mice raised on the same diet. In a study conducted by Knight et al. a similar impact of high-fat diet was observed in 3xTg AD mice that overexpress triple mutations in human APP/MAPT-P301L/PSEN1 and in nontransgenic mice. When raised on a high-fat diet both the transgenics and the control animals displayed considerable weight gain and memory impairments. However, the memory impairments were more severe in the 3xTg mice compared to the controls. It is also interesting that although no significant differences were observed in the amyloid plaques and tau-tangle loads, the brains of 3xTg animals were accompanied by severe microgliosis that was not observed in age-matched controls. This strongly implies the role of neuroinflammation in the development of AD pathogenesis especially when subjected to abnormal dietary conditions (Knight et al., 2014).

Emerging studies have shown that loss of inflammatory mediators prevents insulin resistance, therefore pharmacological targeting of inflammatory pathways improve insulin action. For instance, salicylates activate insulin signaling by inhibiting inflammatory kinases within the cell (Kim M. S. et al., 2013). Similarly, targeting JNK using a synthetic inhibitor has been reported to enhance insulin signaling in obese mice and reduce atherosclerosis in ApoE mutant rodent model (Lee et al., 2003). There are yet other studies which show that thiazolidinediones (TZDs), high-affinity ligands of PPAR γ act as insulin sensitizing agents and improve insulin action by activating lipid metabolism as well as by reducing the production of inflammatory molecules like TNF α (Peraldi et al., 1996).

These studies support a significant correlation between hyperglycemia, impaired insulin resistance, oxidative stress, and inflammation. All these factors are capable of directly impacting A β and tau pathologies as well as triggering a chain of inflammatory stress responses that might eventually lead to neurodegeneration as observed in AD.

AUTOPHAGIC IMPAIRMENTS IN AD AND T2DM

Intracellular accumulation of misfolded protein aggregates is a salient feature of most neurodegenerative diseases (Frake et al., 2015). Autophagy is the process by which such protein aggregates are cleared from the neurons and is important for maintaining neuronal homeostasis. As neurons age they accumulate toxic intracellular protein aggregates and damaged organelles such as mitochondria that must be immediately cleared for the neuron to function at a physiological level (Lee, 2012; Son et al., 2012). Recent studies show that autophagic machinery is also involved in the pathophysiology of T2DM and it regulates the normal function of pancreatic beta cells. Insulin resistance generates oxidative stress on insulin-responsive tissues, enhanced autophagy in these cases acts as a protective factor (Masini et al., 2009). Other than indirect effects, there are studies that report direct impact of insulin resistance on autophagy by an inhibition of the downstream mTOR signaling pathway (Blagosklonny, 2013). Although, the connection between AD and T2DM pathogenesis in terms of autophagic dysfunction is not well documented, in this section we elaborate on the shared pathophysiology of autophagy malfunctioning in these diseases and elaborate on the mechanisms by which insulin resistance might impact autophagy impairment and exacerbate AD pathogenesis.

Autophagy Malfunction in AD

Macroautophagy is the most prevalent form of neuronal autophagy (Frake et al., 2015). In this process, cytoplasmic proteins and organelles are sequestered into double membrane bound structures called autophagosomes (Figure 3). In the next step, the autophagosomes fuse with the lysosomes to form autolysosomes or alternatively with endosomes to form amphisomes before fusing with lysosomes and finally the contents are degraded.

There is a substantial evidence that autophagy is dysregulated in the brains of AD patients. In 2005, Nixon and colleagues used immunogold labeling and electron microscopy techniques on AD brain biopsies of neocortical regions and detected diverse formations of immature autophagic vacuoles (AVs) in the dystrophic neurites (Nixon, 2007). The same phenomenon was also observed in transgenic animal models of AD. A study in PS-1/APP double transgenic mice showed that AVs were formed in dendrites and soma before the appearance of A β plaques compared to age-matched control animals (Nixon et al., 2005). Chen et al. using LC3-EGFP overexpressing 5X FAD mouse models and age-matched controls, observed increased accumulation of autophagosomes in the neurons of FAD-mouse models compared to the controls. This was more prominent under conditions of starvation. Interestingly, the macroautophagy induced by starvation in the transgenic animals was not sufficient to degrade the endogenous A β levels which resulted due to increased cellular uptake of extracellular A β (Chen et al., 2015). The importance of autophagy in the brain was highlighted in a study demonstrating that neuron-specific loss of autophagy proteins (ATG7 and

ATG5) in mice results in neurodegeneration even when other pathological factors are absent (Frake et al., 2015). However, actual mechanisms underlying autophagic dysfunctions in AD has not been fully elucidated. Till date it is a matter of debate as to whether autophagy is the cause or a result of AD.

Presenilins as Autophagy Modulators


Neely et al. has shown that Presenilins play an important role in mediating autophagy as PS-1 has been shown to facilitate N-glycosylation of V0a1 subunit of the lysosomal vacuolar ATPase (v-ATPase) (Neely et al., 2011). FAD-associated mutations in PS-1 and PS-2 leads to an impairment of lysosomal function due to failed acidification of the internal lysosomal contents. This causes an increased accumulation of autophagosomes and a failure to fuse with dysfunctional lysosomes. In their study, Wilson et al. found that in PS-1 $^{-/-}$ neurons both α and β synuclein are mislocalized to the lysosomes of the neuronal cell body and not in the presynaptic regions. The increased accumulation of synuclein suggests that PS-1 deficiencies play a crucial role in developing α -syn lesions in neurodegenerative diseases as observed in familial AD and PD (Wilson et al., 2004). Interestingly, Tung et al. found that non-neuronal and neuronal cells lacking PS-1 displayed reduced levels of p62 protein which serves as a “cargo receptor” for tau degradation. Their study suggests a novel mechanism by which the reduction PS-1 or its mutation in FAD impairs p62-dependent tau clearance (Tung et al., 2014).

A β as an Autophagy Modulator

There is a complex interplay between A β and autophagy. Several studies have shown that autophagy plays a crucial role in A β metabolism including A β production, secretion, and degradation (Nilsson et al., 2015). Autophagy facilitates the degradation and clearance of APP and all APP cleavage products comprising A β and APP-C-terminal-fragments. Deficiency of autophagy protein beclin 1 in cultured neurons and human APP transgenic mice resulted in elevated intraneuronal A β and formation of extracellular amyloid plaques. Overexpression of beclin 1 promoted neuronal autophagy, reduced A β levels, and ameliorated neurodegeneration (Pickford et al., 2008). Autophagy may also play a role in the secretion of A β into extracellular environment where it causes plaque formation. For instance, deletion of ATG7 in APP transgenic mice resulted in less amount of A β secretion and plaque formation (Xiong, 2015).

Interestingly, A β by itself could also be a regulator of autophagy as intracellular A β can activate autophagy by an AKT-dependent pathway or RAGE-CAM κ β -AMPK pathway by induction of mitochondrial ROS generation (Kim et al., 2017). Thus rapamycin, an mTOR inhibitor that upregulates autophagy, is able to reduce both A β pathology in AD mouse models and improve cognition (Spilman et al., 2010).

Several studies indicate that insulin resistance in T2DM inhibits the downstream mTOR pathway and activates autophagy. Insulin resistance also causes ER and oxidative



stress that are capable of inducing autophagy (Quan et al., 2012). Ideally, enhanced autophagy should facilitate A β clearance; however, studies in ATG7 mouse models have shown that increased autophagy may also cause an increased secretion of A β in the extracellular matrix and enhance the deposition of A β plaques (Inoue et al., 2012). Thus, activation of autophagy under conditions of insulin resistance may worsen A β -mediated AD pathogenesis.

Tau and Autophagic Dysfunction

Recent studies suggest that autophagy plays a vital role in tau protein degradation and clearance (Inoue et al., 2012). A study in autophagy-impaired Nrf2 KO mice shows that the levels of phosphorylated and sarcosyl-insoluble tau increases (Jo et al., 2014). In ATG7 conditional KO mouse models the loss of ATG7 from the forebrains of transgenic mice leads to an accumulation of phospho-tau resembling pre-tangle formation within neurons (Inoue et al., 2012). On the restoration of autophagy, the levels of phospho-tau was found to be diminished. It has also been shown that the full-length tau (2N4R) and the caspase cleaved version (tau δ C) are preferentially degraded by macroautophagy, while the truncated version of tau (tau δ 280) is translocated to lysosomes by cell mediated autophagy (CMA) pathway (Dolan and Johnson, 2010).

Recent studies in primary neurons and transgenic P301S mouse models have demonstrated that treatment with autophagy-inducers trehalose and rapamycin reduced insoluble tau levels (Schaeffer et al., 2012; Ozcelik et al., 2013). Conversely, other studies have shown that mammalian target of rapamycin (mTOR) impairs tau clearance by inhibiting autophagy. The TSC1 and TSC2 are negative regulators of mTOR. Consequently, in TSC1/- transgenic mice the elevated levels of endogenous total

and phosphorylated tau suggests an impairment of autophagy (Caccamo et al., 2013; Steele et al., 2013).

Under physiological conditions, tau promotes microtubule assembly and regulates microtubule dynamics (Janning et al., 2014). The microtubular arrays provide tracks for retrograde trafficking and maturation of autophagosomes before fusing with lysosomes in the soma (Kononenko, 2017). In the disease state, hyperphosphorylated tau is capable of disassembly and breakdown of microtubules that could subsequently inhibit retrograde trafficking causing the accumulation of immature autophagosomes within the axons (Rodríguez-Martín et al., 2013).

Autophagic Dysfunction in T2DM That Can Trigger AD Pathogenesis

Insulin resistance in T2DM effectively results in increased oxidative stress that causes the production of ROS leading to damage of intracellular organelles such as ER and mitochondria (Jung et al., 2011). These ER and mitochondrial stress factors are the critical upstream events for the induction of downstream autophagic pathways for the removal and clearance of misfolded proteins in the ER lumen and the dysfunctional ER and mitochondria (Quan et al., 2012). However, during prolonged periods of intracellular stress autophagy pathway becomes inefficient leading to increased accumulation of autophagosomes and impaired clearance. *In vivo* studies in pancreatic beta-cell specific ATG7 KO mice have shown a decrease in the number of pancreatic beta-cells, impaired glucose tolerance, and reduction in insulin secretion (Chen et al., 2011). In addition, these cells accumulate large ubiquitinated proteinaceous materials and p62 implying an autophagic impairment. Supporting these observations, Fujitani et al. demonstrated an increased

accumulation of autophagosomes in the pancreas of db/db mice (Fujitani et al., 2009). In addition, these ATG7-null beta-cells were found to be apoptotic leading to a decreased beta cell mass. When these ATG7 KO mice were crossed to ob/ob mice (a model for obesity with a mutation in the leptin gene) the progeny displayed severe diabetes suggesting that autophagic impairment in obese animals might make them more susceptible to diabetes (Quan et al., 2012). These studies suggest that autophagy acts as a neuroprotective factor in response to ER and mitochondrial stress generated in T2DM.

To elucidate the autophagic impairments underlying AD and T2DM, Jung et al. compared tau pathology and its associated signaling pathways in diabetic OLEF rats and age-matched non-diabetic controls (Jung et al., 2011). The scientists observed an increased accumulation of total and phospho-tau in the soluble fractions of brain extracts from OLEF rats. Interestingly, the increased accumulation of polyubiquitinated tau protein in the neurons of OLEF rats was accompanied by a decrease in p62 protein levels that is responsible for degradation of ubiquitinated tau by autophagy and proteasomal pathways. In a similar study by Carvalho et al. using 3xTgAD and T2DM mouse models, a significant reduction was observed in the levels of autophagy markers ATG7 and LC3-II in the cerebral cortex and hippocampus of both these mice (Carvalho et al., 2015). Pronounced behavioral deficits were observed in these animals that correlated strongly with a reduction of the autophagy markers including the lysosomal marker LAMP1 suggesting an accumulation of autophagosomes and impaired protein clearance in both these models. It can be inferred that the impaired clearance of toxic, soluble aggregates of hyperphosphorylated tau protein is a critical mechanism underlying increased AD-like pathology in T2DM.

Taken together, these results show that firstly insulin resistance in T2DM is capable of inducing prolonged period of oxidative stress which leads to the failure of autophagic machinery and impaired autophagic clearance. This in turn may lead to the progressive build-up of toxic protein aggregates such as A β and tau oligomers and trigger AD pathogenesis. Secondly, under abnormal metabolic conditions or aging, autophagic impairment might be a crucial risk factor for T2DM. This could lead to a vicious cycle in which T2DM can promote tau hyperphosphorylation and induce the accumulation of autophagosomes within the neurons. Impaired autophagic clearance then triggers neurodegenerative events that lead to AD pathogenesis. The crucial role played by autophagy in AD and T2DM opens a new chapter in the development of pro-autophagy drugs that would be used as part of combinatorial therapy in targeting both diseases.

REFERENCES

Abbondante, S., Baglietto-Vargas, D., Rodriguez-Ortiz, C. J., Estrada-Hernandez, T., Medeiros, R., and Laferla, F. M. (2014). Genetic ablation of tau mitigates cognitive impairment induced by type 1 diabetes. *Am. J. Pathol.* 184, 819–826. doi: 10.1016/j.ajpath.2013.11.021

CONCLUSION

In this review we have attempted to summarize the growing body of research that depicts the shared pathophysiology of AD and T2DM and elaborated on the underlying mechanistic pathways at the crossroads of these two diseases. However, it should be noted that almost all the animal models of A β and tau that have been used for preclinical studies are based on FTDP-17 cases and not on sporadic AD models. Although the mechanistic underpinnings that link AD and T2DM could be similar, there is a possibility of considerable variation in the development and propagation of the disease pathology in the familial vs. sporadic cases. This is particularly relevant when designing combinatorial therapies.

A growing body of evidence suggests that the structural and functional integrity of the CNS is compromised in T2DM in the presence of excess insulin or under a condition of insulin resistance. In addition, T2DM impairs glucose metabolism and generates oxidative stress in vital cell organelles. Insulin resistance which is a prominent feature of T2DM is capable of increasing the production and secretion of A β by decreasing proteolysis by IDE. Also, insulin resistance dysregulates the PI3K/AKT/GSK-3 β signaling cascade and generates hyperphosphorylated tau. Insulin resistance leads to loss of synapses, impaired autophagy and increased neuronal apoptosis. These alterations might trigger a cascade of events leading to abnormal A β and tau accumulation culminating in Alzheimer's disease pathology. Hence, targeting brain insulin signaling with pharmacological therapies used for treating T2DM is a novel and compelling approach to treat AD (Morris and Burns, 2012). This has given way to "drug-repositioning" strategies in which pre-existing anti-diabetic drugs are subjected to clinical trials to test their efficacy in AD therapeutics (Watson et al., 2005; Chen et al., 2009; Miller et al., 2011; Moore et al., 2013; Yarchoan and Arnold, 2014; Luchsinger et al., 2016; Femminella et al., 2017).

AUTHOR CONTRIBUTIONS

SC researched articles and prepared the manuscript for the review. AM critically revised the draft before submission.

FUNDING

Funded by European Union's Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement number 705417.

American Diabetes, A. (2009). Diagnosis and classification of diabetes mellitus. *Diabetes Care* 32(Suppl. 1), S62–S67. doi: 10.2337/dc09-S062

Avila, J. (2008). Tau kinases and phosphatases. *J. Cell. Mol. Med.* 12, 258–259. doi: 10.1111/j.1582-4934.2007.00214.x

Avila, J., Leon-Espinosa, G., García, E., García-Escudero, V., Hernández, F., and Defelipe, J. (2012). Tau phosphorylation by GSK3 in different

- conditions. *Int. J. Alzheimers Dis.* 2012;578373. doi: 10.1155/2012/578373
- Avila, J., Wandosell, F., and Hernández, F. (2010). Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. *Expert. Rev. Neurother.* 10, 703–710. doi: 10.1586/ern.10.40
- Back, S. H., and Kaufman, R. J. (2012). Endoplasmic reticulum stress and type 2 diabetes. *Annu. Rev. Biochem.* 81, 767–793. doi: 10.1146/annurev-biochem-072909-095555
- Baglietto-Vargas, D., Shi, J., Yaeger, D. M., Ager, R., and LaFerla, F. M. (2016). Diabetes and Alzheimer's disease crosstalk. *Neurosci. Biobehav. Rev.* 64, 272–287. doi: 10.1016/j.neubiorev.2016.03.005
- Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., et al. (2010). Synthetic amyloid- β oligomers impair long-term memory independently of cellular prion protein. *Proc. Natl. Acad. Sci. U.S.A.* 107, 2295–2300. doi: 10.1073/pnas.0911829107
- Barbagallo, M., and Dominguez, L. J. (2014). Type 2 diabetes mellitus and Alzheimer's disease. *World J. Diabetes* 5, 889–893. doi: 10.4239/wjd.v5.i6.889
- Barron, H., Hafizi, S., Andrezza, A. C., and Mizrahi, R. (2017). Neuroinflammation and oxidative stress in psychosis and psychosis risk. *Int. J. Mol. Sci.* 18:651. doi: 10.3390/ijms18030651
- Basurto-Islas, G., Luna-Munoz, J., Guillozet-Bongaarts, A. L., Binder, L. I., Mena, R., and Garcia-Sierra, F. (2008). Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. *J. Neuropathol. Exp. Neurol.* 67, 470–483. doi: 10.1097/NEN.0b013e31817275c7
- Beckett, L. A., Donohue, M. C., Wang, C., Aisen, P., Harvey, D. J., Saito, N., et al. (2015). The Alzheimer's disease neuroimaging initiative phase 2: increasing the length, breadth, and depth of our understanding. *Alzheimers Dement.* 11, 823–831. doi: 10.1016/j.jalz.2015.05.004
- Bell, K. F., Bennett, D. A., and Cuellar, A. C. (2007). Paradoxical upregulation of glutamatergic presynaptic boutons during mild cognitive impairment. *J. Neurosci.* 27, 10810–10817. doi: 10.1523/JNEUROSCI.3269-07.2007
- Bemiller, S. M., McCray, T. J., Allan, K., Formica, S. V., Xu, G., Wilson, G., et al. (2017). TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. *Mol. Neurodegener.* 12:74. doi: 10.1186/s13024-017-0216-6
- Benedict, C., Hallschmid, M., Schultes, B., Born, J., and Kern, W. (2007). Intranasal insulin to improve memory function in humans. *Neuroendocrinology* 86, 136–142. doi: 10.1159/000106378
- Bertram, L., and Tanzi, R. E. (2009). Genome-wide association studies in Alzheimer's disease. *Hum. Mol. Genet.* 18, R137–R145. doi: 10.1093/hmg/ddp406
- Bierer, L. M., Hof, P. R., Purohit, D. P., Carlin, L., Schmeidler, J., Davis, K. L., et al. (1995). Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. *Arch. Neurol.* 52, 81–88. doi: 10.1001/archneur.1995.00540250089017
- Blagosklonny, M. V. (2013). TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. *Cell Death Dis.* 4:e964. doi: 10.1038/cddis.2013.506
- Blázquez, E., Velázquez, E., Hurtado-Carneiro, V., and Ruiz-Albusac, J. M. (2014). Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. *Front. Endocrinol.* 5:161. doi: 10.3389/fendo.2014.00161
- Boucher, J., Kleinridders, A., and Kahn, C. R. (2014). Insulin receptor signaling in normal and insulin-resistant states. *Cold Spring Harb. Perspect. Biol.* 6:a009191. doi: 10.1101/cshperspect.a009191
- Bradley, C. A., Peineau, S., Taghibiglou, C., Nicolas, C. S., Whitcomb, D. J., Bortolotto, Z. A., et al. (2012). A pivotal role of GSK-3 in synaptic plasticity. *Front. Mol. Neurosci.* 5:13. doi: 10.3389/fnfmol.2012.00013
- Breitner, J. C., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., et al. (2011). Extended results of the Alzheimer's disease anti-inflammatory prevention trial. *Alzheimers Dement.* 7, 402–411. doi: 10.1016/j.jalz.2010.12.014
- Busche, M. A., Chen, X., Henning, H. A., Reichwald, J., Staufenbiel, M., Sakmann, B., et al. (2012). Critical role of soluble amyloid- β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. *Proc. Natl. Acad. Sci. U.S.A.* 109, 8740–8745. doi: 10.1073/pnas.1206171109
- Caccamo, A., Magri, A., Medina, D. X., Wisely, E. V., Lopez-Aranda, M. F., Silva, A. J., et al. (2013). mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. *Aging Cell* 12, 370–380. doi: 10.1111/acer.12057
- Carvalho, C., Santos, M. S., Oliveira, C. R., and Moreira, P. I. (2015). Alzheimer's disease and type 2 diabetes-related alterations in brain mitochondria, autophagy and synaptic markers. *Biochim. Biophys. Acta* 1852, 1665–1675. doi: 10.1016/j.bbadis.2015.05.001
- Chatterjee, S., Sang, T. K., Lawless, G. M., and Jackson, G. R. (2009). Dissociation of tau toxicity and phosphorylation: role of GSK-3 β , MARK and Cdk5 in a *Drosophila* model. *Hum. Mol. Genet.* 18, 164–177. doi: 10.1093/hmg/ddn326
- Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., and Collin, F. (2018). Oxidative stress and the amyloid beta peptide in Alzheimer's disease. *Redox. Biol.* 14, 450–464. doi: 10.1016/j.redox.2017.10.014
- Chen, X., Kondo, K., Motoki, K., Homma, H., and Okazawa, H. (2015). Fasting activates macroautophagy in neurons of Alzheimer's disease mouse model but is insufficient to degrade amyloid- β . *Sci. Rep.* 5:12115. doi: 10.1038/srep12115
- Chen, Y., Zhou, K., Wang, R., Liu, Y., Kwak, Y. D., Ma, T., et al. (2009). Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. *Proc. Natl. Acad. Sci. U.S.A.* 106, 3907–3912. doi: 10.1073/pnas.0807991106
- Chen, Z. F., Li, Y. B., Han, J. Y., Wang, J., Yin, J. J., Li, J. B., et al. (2011). The double-edged effect of autophagy in pancreatic β cells and diabetes. *Autophagy* 7, 12–16. doi: 10.4161/auto.7.1.13607
- Cheng, C. M., Tseng, V., Wang, J., Wang, D., Matyakhina, L., and Bondy, C. A. (2005). Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. *Endocrinology* 146:508. doi: 10.1210/en.2005-0063
- Cheng, D., Noble, J., Tang, M. X., Schupf, N., Mayeux, R., and Luchsinger, J. A. (2011). Type 2 diabetes and late-onset Alzheimer's disease. *Dement. Geriatr. Cogn. Disord.* 31, 424–430. doi: 10.1159/000324134
- Chiang, S. H., Baumann, C. A., Kanzaki, M., Thurmond, D. C., Watson, R. T., Neudauer, C. L., et al. (2001). Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. *Nature* 410, 944–948. doi: 10.1038/35073608
- Choi, B. R., Cho, W. H., Kim, J., Lee, H. J., Chung, C., Jeon, W. K., et al. (2014). Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease. *Exp. Mol. Med.* 46:e75. doi: 10.1038/emmm.2013.147
- Chouliaras, L., Sierksma, A. S., Kenis, G., Prickaerts, J., Lemmens, M. A., Brasnjevic, I., et al. (2010). Gene-environment interaction research and transgenic mouse models of Alzheimer's disease. *Int. J. Alzheimers Dis.* 2010:859101. doi: 10.4061/2010/859101
- Clodfelder-Miller, B., De Sarno, P., Zmijewska, A. A., Song, L., and Jope, R. S. (2005). Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. *J. Biol. Chem.* 280, 39723–39731. doi: 10.1074/jbc.M508824200
- Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., et al. (2011). The acetylation of tau inhibits its function and promotes pathological tau aggregation. *Nat. Commun.* 2:252. doi: 10.1038/ncomms1255
- Cook, C., Stankowski, J. N., Carlomagno, Y., Stetler, C., and Petrucelli, L. (2014). Acetylation: a new key to unlock tau's role in neurodegeneration. *Alzheimers Res. Ther.* 6:29. doi: 10.1186/alzrt259
- Crisuolo, C., Fontebasso, V., Middei, S., Stazi, M., Ammassari-Teule, M., Yan, S. S., et al. (2017). Entorhinal cortex dysfunction can be rescued by inhibition of microglial RAGE in an Alzheimer's disease mouse model. *Sci. Rep.* 7:42370. doi: 10.1038/srep42370
- De Felice, F. G., and Ferreira, S. T. (2014). Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. *Diabetes* 63, 2262–2272. doi: 10.2337/db13-1954
- De Felice, F. G., Lourenco, M. V., and Ferreira, S. T. (2014). How does brain insulin resistance develop in Alzheimer's disease? *Alzheimers Dement.* 10, S26–S32. doi: 10.1016/j.jalz.2013.12.004
- De Felice, F. G., Vieira, M. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., et al. (2009). Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of A β oligomers. *Proc. Natl. Acad. Sci. U.S.A.* 106, 1971–1976. doi: 10.1073/pnas.0809158106

- de la Monte, S. M., and Wands, J. R. (2008). Alzheimer's disease is type 3 diabetes-evidence reviewed. *J. Diabetes Sci. Technol.* 2, 1101–1113. doi: 10.1177/193229680800200619
- De Strooper, B. (2007). Loss-of-function presenilin mutations in Alzheimer disease. *talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep.* 8, 141–146. doi: 10.1038/sj.embor.7400897
- Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., et al. (2012). A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. *J. Clin. Invest.* 122, 1377–1392. doi: 10.1172/JCI58642
- Doens, D., and Fernandez, P. L. (2014). Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis. *J. Neuroinflammation* 11:48. doi: 10.1186/1742-2094-11-48
- Dolan, P. J., and Johnson, G. V. (2010). A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. *J. Biol. Chem.* 285, 21978–21987. doi: 10.1074/jbc.M110.110940
- Dorszewska, J., Predecki, M., Oczkowska, A., Dezor, M., and Kozubski, W. (2016). Molecular basis of familial and sporadic Alzheimer's disease. *Curr. Alzheimer Res.* 13, 952–963. doi: 10.2174/1567205013666160314150501
- Esparza, T. J., Wildburger, N. C., Jiang, H., Gangolli, M., Cairns, N. J., Bateman, R. J., et al. (2016). Soluble amyloid-beta aggregates from human Alzheimer's disease brains. *Sci. Rep.* 6:38187. doi: 10.1038/srep38187
- Farrar, C., Houser, C. R., and Clarke, S. (2005). Activation of the PI3K/Akt signal transduction pathway and increased levels of insulin receptor in protein repair-deficient mice. *Aging Cell* 4, 1–12. doi: 10.1111/j.1474-9728.2004.00136.x
- Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., et al. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain *in vivo*. *Proc. Natl. Acad. Sci. U.S.A.* 100, 4162–4167. doi: 10.1073/pnas.0230450100
- Femminella, G. D., Bencivenga, L., Petraglia, L., Visaggi, L., Gioia, L., Grieco, F. V., et al. (2017). Antidiabetic drugs in Alzheimer's Disease: mechanisms of action and future perspectives. *J. Diabetes Res.* 2017:7420796. doi: 10.1155/2017/7420796
- Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., and De Felice, F. G. (2015). Soluble amyloid-beta oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. *Front. Cell. Neurosci.* 9:191. doi: 10.3389/fncel.2015.00191
- Fjell, A. M., Amlien, I. K., Sneve, M. H., Grydeland, H., Tamnes, C. K., Chaplin, T. A., et al. (2015). The roots of Alzheimer's disease: are high-expanding cortical areas preferentially targeted? *Cereb. Cortex* 25, 2556–2565. doi: 10.1093/cercor/bhu055
- Frake, R. A., Ricketts, T., Menzies, F. M., and Rubinsztein, D. C. (2015). Autophagy and neurodegeneration. *J. Clin. Invest.* 125, 65–74. doi: 10.1172/JCI73944
- Fröjdö, S., Vidal, H., and Pirola, L. (2009). Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. *Biochim. Biophys. Acta* 1792, 83–92. doi: 10.1016/j.bbadis.2008.10.019
- Fujitani, Y., Kawamori, R., and Watada, H. (2009). The role of autophagy in pancreatic β -cell and diabetes. *Autophagy* 5, 280–282. doi: 10.4161/auto.5.2.7656
- Garwood, C. J., Ratcliffe, L. E., Simpson, J. E., Heath, P. R., Ince, P. G., and Wharton, S. B. (2017). Review: Astrocytes in Alzheimer's disease and other age-associated dementias: a supporting player with a central role. *Neuropathol. Appl. Neurobiol.* 43, 281–298. doi: 10.1111/nan.12338
- Gaspar, J. M., Baptista, F. I., Macedo, M. P., and Ambrosio, A. F. (2016). Inside the diabetic brain: role of different players involved in cognitive decline. *ACS Chem. Neurosci.* 7, 131–142. doi: 10.1021/acschemneuro.5b00240
- Gasparini, L., Gouras, G. K., Wang, R., Gross, R. S., Beal, M. F., Greengard, P., et al. (2001). Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. *J. Neurosci.* 21, 2561–2570. doi: 10.1523/JNEUROSCI.21-08-02561.2001
- Gendron, T. F., and Petrucelli, L. (2009). The role of tau in neurodegeneration. *Mol. Neurodegener.* 4:13. doi: 10.1186/1750-1326-4-13
- Gilley, J., Ando, K., Seereeram, A., Rodriguez-Martin, T., Pooler, A. M., Sturdee, L., et al. (2016). Mislocalization of neuronal tau in the absence of tangle pathology in phosphomutant tau knockin mice. *Neurobiol. Aging* 39, 1–18. doi: 10.1016/j.neurobiolaging.2015.11.028
- Gómez-Sintes, R., Hernandez, F., Lucas, J. J., and Avila, J. (2011). GSK-3 mouse models to study neuronal apoptosis and neurodegeneration. *Front. Mol. Neurosci.* 4:45. doi: 10.3389/fnmol.2011.00045
- Gong, C. X., Liu, F., Grundke-Iqbal, I., and Iqbal, K. (2005). Post-translational modifications of tau protein in Alzheimer's disease. *J. Neural Transm.* 112, 813–838. doi: 10.1007/s00702-004-0221-0
- Goure, W. F., Krafft, G. A., Jerecic, J., and Hefti, F. (2014). Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. *Alzheimers Res. Ther.* 6:42. doi: 10.1186/alzrt272
- Gratuzze, M., Julien, J., Petry, F. R., Morin, F., and Planel, E. (2017). Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer's disease-like tau pathology. *Sci. Rep.* 7:46359. doi: 10.1038/srep46359
- Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., et al. (2013). Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid β . *Neuron* 78, 631–643. doi: 10.1016/j.neuron.2013.04.014
- Guerrero-Muñoz, M. J., Gerson, J., and Castillo-Carranza, D. L. (2015). Tau oligomers: the toxic player at Synapses in Alzheimer's Disease. *Front. Cell. Neurosci.* 9:464. doi: 10.3389/fncel.2015.00464
- Haass, C., and Mandelkow, E. (2010). Fyn-tau-amyloid: a toxic triad. *Cell* 142, 356–358. doi: 10.1016/j.cell.2010.07.032
- Haatja, L., Gurlo, T., Huang, C. J., and Butler, P. C. (2008). Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. *Endocr. Rev.* 29, 303–316. doi: 10.1210/er.2007-0037
- Hanover, J. A., and Wang, P. (2013). O-GlcNAc cycling shows neuroprotective potential in *C. elegans* models of neurodegenerative disease. *Worm* 2:e27043. doi: 10.4161/worm.27043
- Hernandez, F., Lucas, J. J., and Avila, J. (2013). GSK3 and tau: two convergence points in Alzheimer's disease. *J. Alzheimers Dis.* 33(Suppl. 1), S141–S144. doi: 10.3233/JAD-2012-129025
- Ho, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., et al. (2004). Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. *FASEB J.* 18, 902–904. doi: 10.1096/fj.03-0978fj
- Holth, J. K., Bomben, V. C., Reed, J. G., Inoue, T., Younkin, L., Younkin, S. G., et al. (2013). Tau loss attenuates neuronal network hyperexcitability in mouse and *Drosophila* genetic models of epilepsy. *J. Neurosci.* 33, 1651–1659. doi: 10.1523/JNEUROSCI.3191-12.2013
- Horvath, J., Herrmann, F. R., Burkhard, P. R., Bouras, C., and Kovari, E. (2013). Neuropathology of dementia in a large cohort of patients with Parkinson's disease. *Parkinsonism Relat. Disord.* 19, 864–868. doi: 10.1016/j.parkreldis.2013.05.010
- Hu, N., Tan, M. S., Sun, L., Jiang, T., Wang, Y. L., Tan, L., et al. (2014). Decreased expression of CD33 in peripheral mononuclear cells of Alzheimer's disease patients. *Neurosci. Lett.* 563, 51–54. doi: 10.1016/j.neulet.2014.01.004
- Huang, C. C., Chung, C. M., Leu, H. B., Lin, L. Y., Chiu, C. C., Hsu, C. Y., et al. (2014). Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study. *PLoS ONE* 9:e87095. doi: 10.1371/journal.pone.0087095
- Huda, M. N., Erdene-Ochir, E., and Pan, C. H. (2017). Assay for phosphorylation and microtubule binding along with localization of tau protein in colorectal cancer cells. *J. Vis. Exp.* doi: 10.3791/55932
- In 't Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M., et al. (1998). NSAIDs and incident Alzheimer's disease. *The Rotterdam Study. Neurobiol. Aging* 19, 607–611. doi: 10.1016/S0197-4580(98)00096-7
- Inoue, K., Rispoli, J., Kaphzan, H., Klann, E., Chen, E. I., Kim, J., et al. (2012). Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway. *Mol. Neurodegener.* 7:48. doi: 10.1186/1750-1326-7-48
- Iqbal, K., Liu, F., Gong, C. X., and Grundke-Iqbal, I. (2010). Tau in Alzheimer disease and related tauopathies. *Curr. Alzheimer Res.* 7, 656–664. doi: 10.2174/156720510793611592
- Irwin, D. J., Cohen, T. J., Grossman, M., Arnold, S. E., McCarty-Wood, E., Van Deerlin, V. M., et al. (2013). Acetylated tau neuropathology in sporadic and hereditary tauopathies. *Am. J. Pathol.* 183, 344–351. doi: 10.1016/j.ajpath.2013.04.025
- Jaeschke, A., Czech, M. P., and Davis, R. J. (2004). An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue. *Genes Dev.* 18, 1976–1980. doi: 10.1101/gad.1216504

- James, B. D., Leurgans, S. E., Hebert, L. E., Scherr, P. A., Yaffe, K., and Bennett, D. A. (2014). Contribution of Alzheimer disease to mortality in the United States. *Neurology* 82, 1045–1050. doi: 10.1212/WNL.0000000000000240
- Janning, D., Igaev, M., Sundermann, F., Bruhmann, J., Beutel, O., Heinisch, J. J., et al. (2014). Single-molecule tracking of tau reveals fast kiss-and-hop interaction with microtubules in living neurons. *Mol. Biol. Cell* 25, 3541–3551. doi: 10.1091/mbc.e14-06-1099
- Jay, T. R., Hirsch, A. M., Broihier, M. L., Miller, C. M., Neilson, L. E., Ransohoff, R. M., et al. (2017). Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. *J. Neurosci.* 37, 637–647. doi: 10.1523/JNEUROSCI.2110-16.2016
- Jiang, T., Yu, J. T., Hu, N., Tan, M. S., Zhu, X. C., and Tan, L. (2014). CD33 in Alzheimer's disease. *Mol. Neurobiol.* 49, 529–535. doi: 10.1007/s12035-013-8536-1
- Jimenez, S., Navarro, V., Moyano, J., Sanchez-Mico, M., Torres, M., Davila, J. C., et al. (2014). Disruption of amyloid plaques integrity affects the soluble oligomers content from Alzheimer disease brains. *PLoS ONE* 9:e114041. doi: 10.1371/journal.pone.0114041
- Jo, C., Gundemir, S., Pritchard, S., Jin, Y. N., Rahman, I., and Johnson, G. V. (2014). Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. *Nat. Commun.* 5:3496. doi: 10.1038/ncomms4496
- Jung, H. J., Kim, Y. J., Eggert, S., Chung, K. C., Choi, K. S., and Park, S. A. (2013). Age-dependent increases in tau phosphorylation in the brains of type 2 diabetic rats correlate with a reduced expression of p62. *Exp. Neurol.* 248, 441–450. doi: 10.1016/j.expneurol.2013.07.013
- Jung, H. J., Park, S. S., Mok, J. O., Lee, T. K., Park, C. S., and Park, S. A. (2011). Increased expression of three-repeat isoforms of tau contributes to tau pathology in a rat model of chronic type 2 diabetes. *Exp. Neurol.* 228, 232–241. doi: 10.1016/j.expneurol.2011.01.012
- Kadavath, H., Hofele, R. V., Biernat, J., Kumar, S., Tepper, K., Urlaub, H., et al. (2015). Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. *Proc. Natl. Acad. Sci. U.S.A.* 112, 7501–7506. doi: 10.1073/pnas.1504081112
- Kaneto, H., Katakami, N., Matsuhisa, M., and Matsuoka, T. A. (2010). Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. *Mediators Inflamm.* 2010:453892. doi: 10.1155/2010/453892
- Karsten, S. L., Sang, T. K., Gehman, L. T., Chatterjee, S., Liu, J., Lawless, G. M., et al. (2006). A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. *Neuron* 51, 549–560. doi: 10.1016/j.neuron.2006.07.019
- Katsube, O., Lin, W. L., Lewis, J., Hutton, M. L., and Dickson, D. W. (2006). Neurofibrillary tangle-related synaptic alterations of spinal motor neurons of P301L tau transgenic mice. *Neurosci. Lett.* 409, 95–99. doi: 10.1016/j.neulet.2006.09.021
- Ke, Y. D., Delerue, F., Gladbach, A., Gotz, J., and Ittner, L. M. (2009). Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. *PLoS ONE* 4:e7917. doi: 10.1371/journal.pone.0007917
- Kim, B., and Feldman, E. L. (2015). Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. *Exp. Mol. Med.* 47:e149. doi: 10.1038/emm.2015.3
- Kim, B., Backus, C., Oh, S., and Feldman, E. L. (2013). Hyperglycemia-induced tau cleavage *in vitro* and *in vivo*: a possible link between diabetes and Alzheimer's disease. *J. Alzheimers Dis.* 34, 727–739. doi: 10.3233/JAD-121669
- Kim, B., Backus, C., Oh, S., Hayes, J. M., and Feldman, E. L. (2009). Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. *Endocrinology* 150, 5294–5301. doi: 10.1210/en.2009-0695
- Kim, I., Lee, K. O., Yun, Y. J., Jeong, J. Y., Kim, E. H., Cheong, H., et al. (2017). Biophysical characterization of Ca²⁺-binding of S100A5 and Ca²⁺-induced interaction with RAGE. *Biochem. Biophys. Res. Commun.* 483, 332–338. doi: 10.1016/j.bbrc.2016.12.143
- Kim, M. S., Yamamoto, Y., Kim, K., Kamei, N., Shimada, T., Liu, L., et al. (2013). Regulation of diet-induced adipose tissue and systemic inflammation by salicylates and pioglitazone. *PLoS ONE* 8:e82847. doi: 10.1371/journal.pone.0082847
- King, M. R., Anderson, N. J., Guernsey, L. S., and Jolivald, C. G. (2013). Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice. *J. Neurosci. Res.* 91, 506–514. doi: 10.1002/jnr.23192
- Knight, E. M., Martins, I. V., Gumusgoz, S., Allan, S. M., and Lawrence, C. B. (2014). High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. *Neurobiol. Aging* 35, 1821–1832. doi: 10.1016/j.neurobiolaging.2014.02.010
- Koenigsnecht, J., and Landreth, G. (2004). Microglial phagocytosis of fibrillar β -amyloid through a beta1 integrin-dependent mechanism. *J. Neurosci.* 24, 9838–9846. doi: 10.1523/JNEUROSCI.2557-04.2004
- Kononenko, N. L. (2017). Lysosomes convene to keep the synapse clean. *J Cell Biol.* 216:2251. doi: 10.1083/jcb.201707070
- Kopeikina, K. J., Polydoro, M., Tai, H. C., Yaeger, E., Carlson, G. A., Pitstick, R., et al. (2013). Synaptic alterations in the rTg4510 mouse model of tauopathy. *J. Comp. Neurol.* 521, 1334–1353. doi: 10.1002/cne.23234
- Kosanam, H., Thai, K., Zhang, Y., Advani, A., Connelly, K. A., Diamandis, E. P., et al. (2014). Diabetes induces lysine acetylation of intermediary metabolism enzymes in the kidney. *Diabetes* 63, 2432–2439. doi: 10.2337/db12-1770
- LaFerla, F. M., and Oddo, S. (2005). Alzheimer's disease: $A\beta$, tau and synaptic dysfunction. *Trends Mol. Med.* 11, 170–176. doi: 10.1016/j.molmed.2005.02.009
- Lathuilière, A., Valdes, P., Papin, S., Cacquevel, M., Maclachlan, C., Knott, G. W., et al. (2017). Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects. *Sci. Rep.* 7:13556. doi: 10.1038/s41598-017-13786-2
- Lauretti, E., Li, J. G., Di Meco, A., and Pratico, D. (2017). Glucose deficit triggers tau pathology and synaptic dysfunction in a tauopathy mouse model. *Transl. Psychiatry* 7:e1020. doi: 10.1038/tp.2016.296
- Lee, E. J., and Park, J. H. (2013). Receptor for advanced glycation endproducts (RAGE), its ligands, and soluble RAGE: potential biomarkers for diagnosis and therapeutic targets for human renal diseases. *Genomics Inform.* 11, 224–229. doi: 10.5808/GI.2013.11.4.224
- Lee, J. A. (2012). Neuronal autophagy: a housekeeper or a fighter in neuronal cell survival? *Exp. Neurobiol.* 21, 1–8. doi: 10.5607/en.2012.21.1.1
- Lee, Y. H., Giraud, J., Davis, R. J., and White, M. F. (2003). c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. *J. Biol. Chem.* 278, 2896–2902. doi: 10.1074/jbc.M208359200
- Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., et al. (1997). The risk of dementia among persons with diabetes mellitus: a population-based cohort study. *Ann. N. Y. Acad. Sci.* 826, 422–427. doi: 10.1111/j.1749-6632.1997.tb48496.x
- Li, S., Jin, M., Koeglsperger, T., Shepardson, N. E., Shankar, G. M., and Selkoe, D. J. (2011). Soluble $A\beta$ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. *J. Neurosci.* 31, 6627–6638. doi: 10.1523/JNEUROSCI.0203-11.2011
- Li, W., Wang, T., and Xiao, S. (2016). Type 2 diabetes mellitus might be a risk factor for mild cognitive impairment progressing to Alzheimer's disease. *Neuropsychiatr. Dis. Treat.* 12, 2489–2495. doi: 10.2147/NDT.S111298
- Li, X. H., Du, L. L., Cheng, X. S., Jiang, X., Zhang, Y., Lv, B. L., et al. (2013). Glycation exacerbates the neuronal toxicity of beta-amyloid. *Cell Death Dis.* 4:e673. doi: 10.1038/cddis.2013.180
- Li, X., Shen, N., Zhang, S., Liu, J., Jiang, Q., Liao, M., et al. (2015b). CD33 rs3865444 polymorphism contributes to alzheimer's disease susceptibility in Chinese, European, and North American Populations. *Mol. Neurobiol.* 52, 414–421. doi: 10.1007/s12035-014-8880-9
- Li, X., Song, D., and Leng, S. X. (2015a). Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. *Clin. Interv. Aging* 10, 549–560. doi: 10.2147/CIA.S74042
- Liu, L. P., Hong, H., Liao, J. M., Wang, T. S., Wu, J., Chen, S. S., et al. (2009). Upregulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice. *Synapse* 63, 636–642. doi: 10.1002/syn.20644
- Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C. X. (2009). Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. *J. Neurochem.* 111, 242–249. doi: 10.1111/j.1471-4159.2009.06320.x
- Locke, M., and Anderson, J. (2011). NF-kappaB activation in organs from STZ-treated rats. *Appl. Physiol. Nutr. Metab.* 36, 121–127. doi: 10.1139/H10-094
- Luchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., et al. (2016). Metformin in amnesic mild cognitive impairment: results of a pilot

- randomized placebo controlled clinical trial. *J. Alzheimers Dis.* 51, 501–514. doi: 10.3233/JAD-150493
- Macauley, S. L., Stanley, M., Caesar, E. E., Yamada, S. A., Raichle, M. E., Perez, R., et al. (2015). Hyperglycemia modulates extracellular amyloid-beta concentrations and neuronal activity *in vivo*. *J. Clin. Invest.* 125, 2463–2467. doi: 10.1172/JCI79742
- Magrane, J., Christensen, R. A., Rosen, K. M., Veereshwarayya, V., and Querfurth, H. W. (2006). Dissociation of ERK and Akt signaling in endothelial cell angiogenic responses to beta-amyloid. *Exp. Cell Res.* 312, 996–1010. doi: 10.1016/j.yexcr.2005.12.009
- Mandelkow, E., and Mandelkow, E. M. (1995). Microtubules and microtubule-associated proteins. *Curr. Opin. Cell Biol.* 7, 72–81. doi: 10.1016/0955-0674(95)80047-6
- Maphis, N., Xu, G., Kokiko-Cochran, O. N., Jiang, S., Cardona, A., Ransohoff, R. M., et al. (2015). Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. *Brain* 138, 1738–1755. doi: 10.1093/brain/awv081
- Marciniak, E., Leboucher, A., Caron, E., Ahmed, T., Tailleux, A., Dumont, J., et al. (2017). Tau deletion promotes brain insulin resistance. *J. Exp. Med.* 214, 2257–2269. doi: 10.1084/jem.20161731
- Marseglia, A., Fratiglioni, L., Laukka, E. J., Santoni, G., Pedersen, N. L., Backman, L., et al. (2016). Early cognitive deficits in Type 2 Diabetes: a population-based study. *J. Alzheimers Dis.* 53, 1069–1078. doi: 10.3233/JAD-160266
- Marzban, L., Park, K., and Verchere, C. B. (2003). Islet amyloid polypeptide and type 2 diabetes. *Exp. Gerontol.* 38, 347–351. doi: 10.1016/S0531-5565(03)00004-4
- Masini, M., Bugliani, M., Lupi, R., del Guerra, S., Boggi, U., Filipponi, F., et al. (2009). Autophagy in human type 2 diabetes pancreatic β cells. *Diabetologia* 52, 1083–1086. doi: 10.1007/s00125-009-1347-2
- Matos, M., Augusto, E., Oliveira, C. R., and Agostinho, P. (2008). Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. *Neuroscience* 156, 898–910. doi: 10.1016/j.neuroscience.2008.08.022
- Michalovicz, L. T., Lally, B., and Konat, G. W. (2015). Peripheral challenge with a viral mimic upregulates expression of the complement genes in the hippocampus. *J. Neuroimmunol.* 285, 137–142. doi: 10.1016/j.jneuroim.2015.06.003
- Miller, B. W., Willett, K. C., and Desilets, A. R. (2011). Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. *Ann. Pharmacother.* 45, 1416–1424. doi: 10.1345/aph.1Q238
- Minkeviciene, R., Rheims, S., Dobszay, M. B., Zilberter, M., Hartikainen, J., Fulop, L., et al. (2009). Amyloid β -induced neuronal hyperexcitability triggers progressive epilepsy. *J. Neurosci.* 29, 3453–3462. doi: 10.1523/JNEUROSCI.5215-08.2009
- Molina, J., Rodriguez-Diaz, R., Fachado, A., Jacques-Silva, M. C., Berggren, P. O., and Caicedo, A. (2014). Control of insulin secretion by cholinergic signaling in the human pancreatic islet. *Diabetes* 63, 2714–2726. doi: 10.2337/db13-1371
- Moore, E. M., Mander, A. G., Ames, D., Kotowicz, M. A., Carne, R. P., Brodaty, H., et al. (2013). Increased risk of cognitive impairment in patients with diabetes is associated with metformin. *Diabetes Care* 36, 2981–2987. doi: 10.2337/dc13-0229
- Moro, M., Phillips, A. S., Gaimster, K., Paul, C., Mudher, A., Nicoll, J., et al. (2018). Pyroglutamate and isospartate modified amyloid-beta in ageing and Alzheimer's disease. *Acta Neuropathol. Commun.* 6:3. doi: 10.1186/s40478-017-0505-x
- Moran, C., Beare, R., Phan, T. G., Bruce, D. G., Callisaya, M. L., Srikanth, V., et al. (2015). Type 2 diabetes mellitus and biomarkers of neurodegeneration. *Neurology* 85, 1123–1130. doi: 10.1212/WNL.0000000000001982
- Moreira, P. I., Santos, M. S., Moreno, A. M., Seica, R., and Oliveira, C. R. (2003). Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. *Diabetes* 52, 1449–1456. doi: 10.2337/diabetes.52.6.1449
- Morel, C., Standen, C. L., Jung, D. Y., Gray, S., Ong, H., Flavell, R. A., et al. (2010). Requirement of JIP1-mediated c-Jun N-terminal kinase activation for obesity-induced insulin resistance. *Mol. Cell Biol.* 30, 4616–4625. doi: 10.1128/MCB.00585-10
- Morimoto, K., Horio, J., Satoh, H., Sue, L., Beach, T., Arita, S., et al. (2011). Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology. *J. Alzheimers Dis.* 25, 59–76. doi: 10.3233/JAD-2011-101815
- Morris, J. K., and Burns, J. M. (2012). Insulin: an emerging treatment for Alzheimer's disease dementia? *Curr. Neurol. Neurosci. Rep.* 12, 520–527. doi: 10.1007/s11910-012-0297-0
- Mosconi, L., Pupi, A., and De Leon, M. J. (2008). Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. *Ann. N. Y. Acad. Sci.* 1147, 180–195. doi: 10.1196/annals.1427.007
- Mucke, L., and Selkoe, D. J. (2012). Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. *Cold Spring Harb. Perspect. Med.* 2:a006338. doi: 10.1101/cshperspect.a006338
- Mudher, A., Shepherd, D., Newman, T. A., Mildren, P., Jukes, J. P., Squire, A., et al. (2004). GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. *Mol. Psychiatry* 9, 522–530. doi: 10.1038/sj.mp.4001483
- Mullins, R. J., Diehl, T. C., Chia, C. W., and Kapogiannis, D. (2017). Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer's disease. *Front. Aging Neurosci.* 9:118. doi: 10.3389/fnagi.2017.00118
- Neely, K. M., Green, K. N., and LaFerla, F. M. (2011). Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a gamma-secretase-independent manner. *J. Neurosci.* 31, 2781–2791. doi: 10.1523/JNEUROSCI.5156-10.2010
- Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., et al. (2012). Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *J. Neuropathol. Exp. Neurol.* 71, 362–381. doi: 10.1097/NEN.0b013e31825018f7
- Niewidok, B., Igaev, M., Sundermann, F., Janning, D., Bakota, L., and Brandt, R. (2016). Presence of a carboxy-terminal pseudorepeat and disease-like pseudohyperphosphorylation critically influence tau's interaction with microtubules in axon-like processes. *Mol. Biol. Cell* 27, 3537–3549. doi: 10.1091/mbc.e16-06-0402
- Nilsson, P., Sekiguchi, M., Akagi, T., Izumi, S., Komori, T., Hui, K., et al. (2015). Autophagy-related protein 7 deficiency in amyloid β (Abeta) precursor protein transgenic mice decreases Abeta in the multivesicular bodies and induces Abeta accumulation in the Golgi. *Am. J. Pathol.* 185, 305–313. doi: 10.1016/j.ajpath.2014.10.011
- Nixon, R. A. (2007). Autophagy, amyloidogenesis and Alzheimer disease. *J. Cell. Sci.* 120(Pt 23), 4081–4091. doi: 10.1242/jcs.019265
- Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., et al. (2005). Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. *J. Neuropathol. Exp. Neurol.* 64, 113–122. doi: 10.1093/jnen/64.2.113
- Nizari, S., Carare, R. O., and Hawkes, C. A. (2016). Increased Abeta pathology in aged Tg2576 mice born to mothers fed a high fat diet. *Sci. Rep.* 6:21981. doi: 10.1038/srep21981
- Nowotny, K., Jung, T., Hohn, A., Weber, D., and Grune, T. (2015). Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. *Biomolecules* 5, 194–222. doi: 10.3390/biom5010194
- Orr, M. E., and Oddo, S. (2013). Autophagic/lysosomal dysfunction in Alzheimer's disease. *Alzheimers Res. Ther.* 5:53. doi: 10.1186/alzrt217
- Ozcan, U., Cao, Q., Yilmaz, E., Lee, A. H., Iwakoshi, N. N., Ozdelen, E., et al. (2004). Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science* 306, 457–461. doi: 10.1126/science.1103160
- Ozcelik, S., Fraser, G., Castets, P., Schaeffer, V., Skachokova, Z., Breu, K., et al. (2013). Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. *PLoS ONE* 8:e62459. doi: 10.1371/journal.pone.0062459
- Palop, J. J., and Mucke, L. (2010). Amyloid- β -induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. *Nat. Neurosci.* 13, 812–818. doi: 10.1038/nn.2583
- Patel, S., and Santani, D. (2009). Role of NF-kappa B in the pathogenesis of diabetes and its associated complications. *Pharmacol. Rep.* 61, 595–603. doi: 10.1016/S1734-1140(09)70111-2
- Peila, R., Rodriguez, B. L., Launer, L. J., and Honolulu-Asia Aging Study. (2002). Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the honolulu-asia aging study. *Diabetes* 51, 1256–1262. doi: 10.2337/diabetes.51.4.1256

- Peraldi, P., Hotamisligil, G. S., Buurman, W. A., White, M. F., and Spiegelman, B. M. (1996). Tumor necrosis factor (TNF)- α inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. *J. Biol. Chem.* 271, 13018–13022. doi: 10.1074/jbc.271.22.13018
- Pickford, F., Masliah, E., Britschgi, M., Lucin, K., Narasimhan, R., Jaeger, P. A., et al. (2008). The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. *J. Clin. Invest.* 118, 2190–2199. doi: 10.1172/JCI33585
- Planel, E., Tatebayashi, Y., Miyasaka, T., Liu, L., Wang, L., Herman, M., et al. (2007). Insulin dysfunction induces *in vivo* tau hyperphosphorylation through distinct mechanisms. *J. Neurosci.* 27, 13635–13648. doi: 10.1523/JNEUROSCI.3949-07.2007
- Plum, L., Schubert, M., and Bruning, J. C. (2005). The role of insulin receptor signaling in the brain. *Trends Endocrinol. Metab.* 16, 59–65. doi: 10.1016/j.tem.2005.01.008
- Pooler, A. M., Noble, W., and Hanger, D. P. (2014). A role for tau at the synapse in Alzheimer's disease pathogenesis. *Neuropharmacology* 76(Pt A), 1–8. doi: 10.1016/j.neuropharm.2013.09.018
- Puzzo, D., Piacentini, R., Fa, M., Gulisano, W., Li Puma, D. D., Staniszewski, A., et al. (2017). LTP and memory impairment caused by extracellular A β and Tau oligomers is APP-dependent. *Life* 6:e26991. doi: 10.7554/eLife.26991
- Qiu, W. Q., and Folstein, M. F. (2006). Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. *Neurobiol. Aging* 27, 190–198. doi: 10.1016/j.neurobiolaging.2005.01.004
- Qu, Z. S., Li, L., Sun, X. J., Zhao, Y. W., Zhang, J., Geng, Z., et al. (2014). Glycogen synthase kinase-3 regulates production of amyloid- β peptides and tau phosphorylation in diabetic rat brain. *ScientificWorldJournal* 2014:878123. doi: 10.1155/2014/878123
- Qu, Z., Jiao, Z., Sun, X., Zhao, Y., Ren, J., and Xu, G. (2011). Effects of streptozotocin-induced diabetes on tau phosphorylation in the rat brain. *Brain Res.* 1383, 300–306. doi: 10.1016/j.brainres.2011.01.084
- Quan, W., Lim, Y. M., and Lee, M. S. (2012). Role of autophagy in diabetes and endoplasmic reticulum stress of pancreatic β -cells. *Exp. Mol. Med.* 44, 81–88. doi: 10.3858/emmm.2012.44.2.030
- Quraishe, S., Cowan, C. M., and Mudher, A. (2013). NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. *Mol. Psychiatry* 18, 834–842. doi: 10.1038/mp.2013.32
- Reddy, P. H. (2013). Amyloid beta-induced glycogen synthase kinase 3 β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damage. *Biochim. Biophys. Acta* 1832, 1913–1921. doi: 10.1016/j.bbadis.2013.06.012
- Reno, C. M., Puente, E. C., Sheng, Z., Daphna-Iken, D., Bree, A. J., Routh, V. H., et al. (2017). Brain GLUT4 knockout mice have impaired glucose tolerance, decreased insulin sensitivity, and impaired hypoglycemic counterregulation. *Diabetes* 66, 587–597. doi: 10.2337/db16-0917
- Roberts, R. O., Knopman, D. S., Przybelski, S. A., Mielke, M. M., Kantarci, K., Preboske, G. M., et al. (2014). Association of type 2 diabetes with brain atrophy and cognitive impairment. *Neurology* 82, 1132–1141. doi: 10.1212/WNL.0000000000000269
- Robertson, L. A., Moya, K. L., and Breen, K. C. (2004). The potential role of tau protein O-glycosylation in Alzheimer's disease. *J. Alzheimers Dis.* 6, 489–495. doi: 10.3233/JAD-2004-6505
- Rodríguez-Martín, T., Cuchillo-Ibanez, I., Noble, W., Nyenya, F., Anderton, B. H., and Hanger, D. P. (2013). Tau phosphorylation affects its axonal transport and degradation. *Neurobiol. Aging* 34, 2146–2157. doi: 10.1016/j.neurobiolaging.2013.03.015
- Rodríguez-Rodríguez, P., Sandebring-Matton, A., Merino-Serrais, P., Parrado-Fernandez, C., Rabano, A., Winblad, B., et al. (2017). Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons. *Brain* 140, 3269–3285. doi: 10.1093/brain/awx256
- Romeo, G., Liu, W. H., Asnaghi, V., Kern, T. S., and Lorenzi, M. (2002). Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. *Diabetes* 51, 2241–2248. doi: 10.2337/diabetes.51.7.2241
- Rubio-Perez, J. M., and Morillas-Ruiz, J. M. (2012). A review: inflammatory process in Alzheimer's disease, role of cytokines. *ScientificWorldJournal* 2012:756357. doi: 10.1100/2012/756357
- Sakono, M., and Zako, T. (2010). Amyloid oligomers: formation and toxicity of A β oligomers. *FEBS J.* 277, 1348–1358. doi: 10.1111/j.1742-4658.2010.07568.x
- Samuel, S., Zhang, K., Tang, Y. D., Gerdes, A. M., and Carrillo-Sepulveda, M. A. (2017). Triiodothyronine potentiates vasorelaxation via PKG/VASP signaling in vascular smooth muscle cells. *Cell. Physiol. Biochem.* 41, 1894–1904. doi: 10.1159/000471938
- Savu, O., Bradescu, O. M., Serafinceanu, C., Iosif, L., Tirgoviste, C. I., and Stoian, I. (2013). Erythrocyte caspase-3 and antioxidant defense is activated in red blood cells and plasma of type 2 diabetes patients at first clinical onset. *Redox Rep.* 18, 56–62. doi: 10.1179/1351000213Y.0000000040
- Schaeffer, V., Lavenir, I., Ozcelik, S., Tolnay, M., Winkler, D. T., and Goedert, M. (2012). Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. *Brain* 135, 2169–2177. doi: 10.1093/brain/aww143
- Schedin-Weiss, S., Winblad, B., and Tjernberg, L. O. (2014). The role of protein glycosylation in Alzheimer disease. *FEBS J.* 281, 46–62. doi: 10.1111/febs.12590
- Schmitz, T. W., Nathan Spreng, R., and Alzheimer's Disease Neuroimaging Initiative. (2016). Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. *Nat. Commun.* 7:13249. doi: 10.1038/ncomms13249
- Schubert, M., Brazil, D. P., Burks, D. J., Kushner, J. A., Ye, J., Flint, C. L., et al. (2003). Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. *J. Neurosci.* 23, 7084–7092. doi: 10.1523/JNEUROSCI.23-18-07084.2003
- Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., et al. (2004). Role for neuronal insulin resistance in neurodegenerative diseases. *Proc. Natl. Acad. Sci. U.S.A.* 101, 3100–3105. doi: 10.1073/pnas.0308724101
- Sekar, S., McDonald, J., Cuyugan, L., Aldrich, J., Kurdoglu, A., Adkins, J., et al. (2015). Alzheimer's disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. *Neurobiol. Aging* 36, 583–591. doi: 10.1016/j.neurobiolaging.2014.09.027
- Selkoe, D. J. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. *Behav. Brain Res.* 192, 106–113. doi: 10.1016/j.bbr.2008.02.016
- Serpell, L. C., Blake, C. C., and Fraser, P. E. (2000). Molecular structure of a fibrillar Alzheimer's A beta fragment. *Biochemistry* 39, 13269–13275. doi: 10.1021/bi000637v
- Serrano-Pozo, A., Froesch, M. P., Masliah, E., and Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. *Cold Spring Harb. Perspect. Med.* 1:a006189. doi: 10.1101/cshperspect.a006189
- Shankar, G. M., and Walsh, D. M. (2009). Alzheimer's disease: synaptic dysfunction and Abeta. *Mol. Neurodegener.* 4:48. doi: 10.1186/1750-1326-4-48
- Sheng, M., Sabatini, B. L., and Sudhof, T. C. (2012). Synapses and Alzheimer's disease. *Cold Spring Harb. Perspect. Biol.* 4:a005777. doi: 10.1101/cshperspect.a005777
- Showkat, M., Beigh, M. A., and Andrabi, K. I. (2014). mTOR signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions. *Mol. Biol. Int.* 2014:686984. doi: 10.1155/2014/686984
- Smet-Nocca, C., Broncel, M., Wieruszkeski, J. M., Tokarski, C., Hanouille, X., Leroy, A., et al. (2011). Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation. *Mol. Biosyst.* 7, 1420–1429. doi: 10.1039/c0mb00337a
- Solito, E., and Sastre, M. (2012). Microglia function in Alzheimer's disease. *Front. Pharmacol.* 3:14. doi: 10.3389/fphar.2012.00014
- Son, J. H., Shim, J. H., Kim, K. H., Ha, J. Y., and Han, J. Y. (2012). Neuronal autophagy and neurodegenerative diseases. *Exp. Mol. Med.* 44, 89–98. doi: 10.3858/emmm.2012.44.2.031
- Son, S. M., Cha, M. Y., Choi, H., Kang, S., Choi, H., Lee, M. S., et al. (2016). Insulin-degrading enzyme secretion from astrocytes is mediated by an autophagy-based unconventional secretory pathway in Alzheimer disease. *Autophagy* 12, 784–800. doi: 10.1080/15548627.2016.1159375
- Sotiropoulos, I., Galas, M. C., Silva, J. M., Skoulakis, E., Wegmann, S., Maina, M. B., et al. (2017). Atypical, non-standard functions of the microtubule associated Tau protein. *Acta Neuropathol. Commun.* 5:91. doi: 10.1186/s40478-017-0489-6
- Spilman, P., Podlutska, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., et al. (2010). Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid- β levels in a mouse model of Alzheimer's disease. *PLoS ONE* 5:e9979. doi: 10.1371/journal.pone.0009979

- Spires-Jones, T. L., and Hyman, B. T. (2014). The intersection of amyloid beta and tau at synapses in Alzheimer's disease. *Neuron* 82, 756–771. doi: 10.1016/j.neuron.2014.05.004
- Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D., et al. (2011). Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. *Neurobiol. Aging* 32, 763–777. doi: 10.1016/j.neurobiolaging.2009.04.016
- Stanley, M., Macauley, S. L., and Holtzman, D. M. (2016). Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence? *J. Exp. Med.* 213, 1375–1385. doi: 10.1084/jem.20160493
- Steele, J. W., Fan, E., Kelahmetoglu, Y., Tian, Y., and Bustos, V. (2013). Modulation of Autophagy as a Therapeutic Target for Alzheimer's Disease. *Postdoc J* 1, 21–34.
- Stoothoff, W. H., and Johnson, G. V. (2005). Tau phosphorylation, physiological and pathological consequences. *Biochim. Biophys. Acta* 1739, 280–297. doi: 10.1016/j.bbadis.2004.06.017
- Swaroop, J. J., Rajarajeswari, D., and Naidu, J. N. (2012). Association of TNF- α with insulin resistance in type 2 diabetes mellitus. *Indian J. Med. Res.* 135, 127–130. doi: 10.4103/0971-5916.93435
- Tackenberg, C., and Brandt, R. (2009). Divergent pathways mediate spine alterations and cell death induced by amyloid- β , wild-type tau, and R406W tau. *J. Neurosci.* 29, 14439–14450. doi: 10.1523/JNEUROSCI.3590-09.2009
- Tai, H. C., Serrano-Pozo, A., Hashimoto, T., Frosch, M. P., Spires-Jones, T. L., and Hyman, B. T. (2012). The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. *Am. J. Pathol.* 181, 1426–1435. doi: 10.1016/j.ajpath.2012.06.033
- Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D., et al. (2010). Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and A β deposition in an Alzheimer mouse model with diabetes. *Proc. Natl. Acad. Sci. U.S.A.* 107, 7036–7041. doi: 10.1073/pnas.1000645107
- Talbot, K. (2014). Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. *Neurodegener. Dis. Manag.* 4, 31–40. doi: 10.2217/nmt.13.73
- Talbot, K., Wang, H. Y., Kazi, H., Han, L. Y., Bakshi, K. P., Stucky, A., et al. (2012). Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. *J. Clin. Invest.* 122, 1316–1338. doi: 10.1172/JCI59903
- Taylor, R. (2012). Insulin resistance and type 2 diabetes. *Diabetes* 61, 778–779. doi: 10.2337/db12-0073
- Thiels, E., and Klann, E. (2001). Extracellular signal-regulated kinase, synaptic plasticity, and memory. *Rev. Neurosci.* 12, 327–345. doi: 10.1515/REVNEURO.2001.12.4.327
- Tosto, G., and Reitz, C. (2013). Genome-wide association studies in Alzheimer's disease: a review. *Curr. Neurol. Neurosci. Rep.* 13:381. doi: 10.1007/s11910-013-0381-0
- Trzeciakiewicz, H., Tseng, J. H., Wander, C. M., Madden, V., Tripathy, A., Yuan, C. X., et al. (2017). A dual pathogenic mechanism links tau acetylation to sporadic tauopathy. *Sci. Rep.* 7:44102. doi: 10.1038/srep44102
- Tung, Y. T., Wang, B. J., Hsu, W. M., Hu, M. K., Her, G. M., Huang, W. P., et al. (2014). Presenilin-1 regulates the expression of p62 to govern p62-dependent tau degradation. *Mol. Neurobiol.* 49, 10–27. doi: 10.1007/s12035-013-8482-y
- Tyan, S. H., Shih, A. Y., Walsh, J. J., Maruyama, H., Sarsoza, F., Ku, L., et al. (2012). Amyloid precursor protein (APP) regulates synaptic structure and function. *Mol. Cell Neurosci.* 51, 43–52. doi: 10.1016/j.mcn.2012.07.009
- Ulrich, J. D., Ulland, T. K., Colonna, M., and Holtzman, D. M. (2017). Elucidating the role of TREM2 in Alzheimer's Disease. *Neuron* 94, 237–248. doi: 10.1016/j.neuron.2017.02.042
- Umegaki, H. (2014). Type 2 diabetes as a risk factor for cognitive impairment: current insights. *Clin. Interv. Aging* 9, 1011–1019. doi: 10.2147/CIA.S48926
- Uranga, R. M., Katz, S., and Salvador, G. A. (2013). Enhanced phosphatidylinositol 3-kinase (PI3K)/Akt signaling has pleiotropic targets in hippocampal neurons exposed to iron-induced oxidative stress. *J. Biol. Chem.* 288, 19773–19784. doi: 10.1074/jbc.M113.457622
- van Bussel, F. C., Backes, W. H., Hofman, P. A., Puts, N. A., Edden, R. A., van Boxtel, M. P., et al. (2016). Increased GABA concentrations in type 2 diabetes mellitus are related to lower cognitive functioning. *Medicine* 95:e4803. doi: 10.1097/MD.0000000000004803
- van der Flier, W. M., and Scheltens, P. (2005). Epidemiology and risk factors of dementia. *J. Neurol. Neurosurg. Psychiatry* 76 (Suppl. 5), v2–v7. doi: 10.1136/jnnp.2005.082867
- van der Heide, L. P., Kamal, A., Artola, A., Gispen, W. H., and Ramakers, G. M. (2005). Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-D-aspartate receptor and phosphatidylinositol-3-kinase-dependent manner. *J. Neurochem.* 94, 1158–1166. doi: 10.1111/j.1471-4159.2005.03269.x
- Van Eldik, L. J., Carrillo, M. C., Cole, P. E., Feuerbach, D., Greenberg, B. D., Hendrix, J. A., et al. (2016). The roles of inflammation and immune mechanisms in Alzheimer's disease. *Alzheimers Dement.* 2, 99–109. doi: 10.1016/j.trci.2016.05.001
- Vassar, R. (2004). BACE1: the beta-secretase enzyme in Alzheimer's disease. *J. Mol. Neurosci.* 23, 105–114. doi: 10.1385/JMN:23:1-2:105
- Verkhatsky, A., Olabarria, M., Noristani, H. N., Yeh, C. Y., and Rodriguez, J. J. (2010). Astrocytes in Alzheimer's disease. *Neurotherapeutics* 7, 399–412. doi: 10.1016/j.nurt.2010.05.017
- Vlassenko, A. G., Benzinger, T. L., and Morris, J. C. (2012). PET amyloid-beta imaging in preclinical Alzheimer's disease. *Biochim. Biophys. Acta* 1822, 370–379. doi: 10.1016/j.bbadis.2011.11.005
- Wang, J. Z., Grundke-Iqbal, I., and Iqbal, K. (1996). Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease. *Nat. Med.* 2, 871–875. doi: 10.1038/nm0896-871
- Watson, G. S., Cholerton, B. A., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., et al. (2005). Preserved cognition in patients with early Alzheimer disease and amnesic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. *Am. J. Geriatr. Psychiatry* 13, 950–958. doi: 10.1176/appi.ajgp.13.11.950
- Wellen, K. E., and Hotamisligil, G. S. (2005). Inflammation, stress, and diabetes. *J. Clin. Invest.* 115, 1111–1119. doi: 10.1172/JCI25102
- Wennberg, A. M., Spira, A. P., Pettigrew, C., Soldan, A., Zipunnikov, V., Rebok, G. W., et al. (2016). Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults. *J. Neurol. Sci.* 365, 89–95. doi: 10.1016/j.jns.2016.04.017
- Wes, P. D., Easton, A., Corradi, J., Barten, D. M., Devidze, N., DeCarr, L. B., et al. (2014). Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer's disease. *PLoS ONE* 9:e106050. doi: 10.1371/journal.pone.0106050
- Wildsmith, K. R., Holley, M., Savage, J. C., Skerrett, R., and Landreth, G. E. (2013). Evidence for impaired amyloid beta clearance in Alzheimer's disease. *Alzheimers Res. Ther.* 5:33. doi: 10.1186/alzrt187
- Wilson, C. A., Murphy, D. D., Giasson, B. I., Zhang, B., Trojanowski, J. Q., and Lee, V. M. (2004). Degradative organelles containing mislocalized α - and α -synuclein proliferate in presenilin-1 null neurons. *J. Cell Biol.* 165, 335–346. doi: 10.1083/jcb.200403061
- Wilson, D. M., and Binder, L. I. (1997). Free fatty acids stimulate the polymerization of tau and amyloid beta peptides, *in vitro* evidence for a common effector of pathogenesis in Alzheimer's disease. *Am. J. Pathol.* 150, 2181–2195.
- Wu, J., Nie, S. D., and Wang, S. (2013). Tau pathology in diabetes mellitus. *Pharmazie* 68, 649–652.
- Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., et al. (2003). Adult mouse astrocytes degrade amyloid- β *in vitro* and *in situ*. *Nat. Med.* 9, 453–457. doi: 10.1038/nm838
- Wyss-Coray, T., and Rogers, J. (2012). Inflammation in Alzheimer disease—a brief review of the basic science and clinical literature. *Cold Spring Harb. Perspect. Med.* 2:a006346. doi: 10.1101/cshperspect.a006346
- Xiong, J. (2015). Atg7 in development and disease: panacea or Pandora's Box? *Protein Cell* 6, 722–734. doi: 10.1007/s13238-015-0195-8
- Yarchoan, M., and Arnold, S. E. (2014). Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. *Diabetes* 63, 2253–2261. doi: 10.2337/db14-0287
- Yiannopoulou, K. G., and Papageorgiou, S. G. (2013). Current and future treatments for Alzheimer's disease. *Ther. Adv. Neurol. Disord.* 6, 19–33. doi: 10.1177/1756285612461679

- Yin, Y., Chen, F., Wang, W., Wang, H., and Zhang, X. (2017). Resolvin D1 inhibits inflammatory response in STZ-induced diabetic retinopathy rats: possible involvement of NLRP3 inflammasome and NF-kappaB signaling pathway. *Mol. Vis.* 23, 242–250.
- Yoon, M. S. (2017). The role of mammalian target of rapamycin (mTOR) in insulin signaling. *Nutrients* 9:E1176. doi: 10.3390/nu9111176
- Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C., et al. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. *Neuron* 53, 337–351. doi: 10.1016/j.neuron.2007.01.010
- Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., et al. (2012). Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. *Nat. Chem. Biol.* 8, 393–399. doi: 10.1038/nchembio.797
- Zhang, W., Thompson, B. J., Hietakangas, V., and Cohen, S. M. (2011). MAPK/ERK signaling regulates insulin sensitivity to control glucose metabolism in *Drosophila*. *PLoS Genet.* 7:e1002429. doi: 10.1371/journal.pgen.1002429
- Zhao, R., Hu, W., Tsai, J., Li, W., and Gan, W. B. (2017). Microglia limit the expansion of beta-amyloid plaques in a mouse model of Alzheimer's disease. *Mol. Neurodegener.* 12:47. doi: 10.1186/s13024-017-0188-6
- Zhao, W. Q., and Townsend, M. (2009). Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. *Biochim. Biophys. Acta* 1792, 482–496. doi: 10.1016/j.bbadis.2008.10.014
- Zhu, Y., Shan, X., Yuzwa, S. A., and Vocadlo, D. J. (2014). The emerging link between O-GlcNAc and Alzheimer disease. *J. Biol. Chem.* 289, 34472–34481. doi: 10.1074/jbc.R114.601351
- Zilka, N., Filipcik, P., Koson, P., Fialova, L., Skrabana, R., Zilkova, M., et al. (2006). Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration *in vivo*. *FEBS Lett.* 580, 3582–3588. doi: 10.1016/j.febslet.2006.05.029
- Zotova, E., Nicoll, J. A., Kalaria, R., Holmes, C., and Boche, D. (2010). Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. *Alzheimers Res. Ther.* 2:1. doi: 10.1186/alzrt24

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Chatterjee and Mudher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.